{
  "doc_id": "2018-10-01_Informationen-zVT_Lenvatinib-D-379",
  "created_date": "2017",
  "country": "DE",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "Kriterien\nVergleic",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "und",
      "text": "Recherc\nder zwec\nSGB V\nVorgang\nStand: Dezem\nn zur Best\nchstherapi",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "che und Sy",
      "text": "ckmäßige\ng: 2017-B-\nmber 2017\ntimmung der zwe\nie\nSynopse der Evid\nen Vergleichsther\n-221 Lenvatinib\neck\nden\nrap\nkmäßig\nnz zur B\npie nach\ngen\nBestimmung\nh § 35a",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "I. Zweckmäßige Vergleichstherapie: Kriterien gemäß 5. Kapitel § 6 VerfO G-BA",
      "text": "Lenvatinib\n[zur Behandlung des Leberzellkarzinoms]",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "Kriterien gemäß 5. Kapitel § 6 VerfO",
      "text": "Sofern als Vergleichstherapie eine Arzneimittelanwendung in\nBetracht kommt, muss das Arzneimittel grundsätzlich eine Siehe Übersicht „II. Zugelassene Arzneimittel im Anwendungsgebiet“\nZulassung für das Anwendungsgebiet haben.\nSofern als Vergleichstherapie eine nicht-medikamentöse Eine nicht-medikamentöse Behandlung kommt als zweckmäßige Vergleichstherapie nicht in\nBehandlung in Betracht kommt, muss diese im Rahmen der Betracht. Hierbei wird davon ausgegangen, dass sowohl eine kurative Behandlung (entsprechend\nGKV erbringbar sein.\nBCLC-Stadium 0 und A) als auch eine lokoregionäre Therapie im BCLC-Stadium B, insbesondere\neine transarterielle (Chemo)-Embolisation (TACE oder TAE), nicht (mehr) infrage kommt.\nBeschlüsse/Bewertungen/Empfehlungen des Gemeinsamen • Maßnahmen zur Qualitätssicherung bei Protonentherapie bei Patientinnen und Patienten mit\nBundesausschusses zu im Anwendungsgebiet zugelassenen inoperablem hepatozellulärem Karzinom; Beschluss vom 16. Juli 2009 und 27. November 2015\nArzneimitteln/nicht-medikamentösen Behandlungen • Bewertung nach § 137h SGB V: Ultraschallgesteuerter hoch-intensiverfokussierter Ultraschall\nzur Behandlung des hepatozellulären Karzinoms ; Beschluss vom 16. März 2017\nDie Vergleichstherapie soll nach dem allgemein anerkannten\nStand der medizinischen Erkenntnisse zur zweckmäßigen Siehe systematische Literaturrecherche\nTherapie im Anwendungsgebiet gehören.\nII. Zugelassene Arzneimittel im Anwendungsge\nWirkstoff\nAnwendungsgebiet\nATC-Code\n(Text aus Beratungsanforderung/Fachinfo",
      "start_page": 2,
      "end_page": 3
    },
    {
      "heading": "Handelsname",
      "text": "Zu bewertendes Arzneimittel:\nLenvatinib Vorläufig geplantes Anwendungsgebiet:\nL01XE29 Lenvatinib ist angezeigt zur Behandlung des Leberzellkarzinoms\nLenvima®\nMitomycin Mitomycin wird in der palliativen Tumortherapie eingesetzt.\nL01DC03 Bei intravenöser Gabe ist es in der Monochemotherapie oder in kombinierter zytostatisc\n(generisch) metastasierenden Tumoren wirksam: […]\n− fortgeschrittenes Leberzellkarzinom\nSorafenib Leberzellkarzinom\nL01XE05 Nexavar ist angezeigt zur Behandlung des Leberzellkarzinoms (siehe Abschnitt 5.1).\nNexavar®\nRegorafenib1 Stivarga ist angezeigt als Monotherapie zur Behandlung von erwachsenen Patienten m\nL01 XE21 - hepatozellulärem Karzinom (HCC), die zuvor mit Sorafenib behandelt wurden.\nStivarga®\nQuellen: AMIS-Datenbank, Fachinformationen\n1 Regorafenib ist derzeit in Deutschland nicht im Handel.\nebiet\normation)\ncher Che\nmit: […]\nemothera\napie bei\nfolgende\nen\nRecherc\nder zwe\n§ 35a S\nVorgan\nDatum:\nche und Sy\neckmäßigen\nSGB V\nng: 2017-B-2\nynopse\nn Verg\n221 (Le\ne der\ngleich\nenva\nr Evi\nhsthe\natinib\nide\nera\nb)\nenz\nap\nz zur Bestimmung\npie nach\nRecherche und Synopse der Evidenz zur Bestimmung der\nzweckmäßigen Vergleichstherapie (zVT):",
      "start_page": 3,
      "end_page": 5
    },
    {
      "heading": "Systematische Recherche:",
      "text": "Es wurde eine systematische Literaturrecherche nach systematischen Reviews, Meta-Analysen, HTA-\nBerichten und evidenzbasierten systematischen Leitlinien zur Indikation Leberzellkarzinom\ndurchgeführt. Der Suchzeitraum wurde auf die letzten 5 Jahre eingeschränkt und die Recherche am\n02.10.2017 abgeschlossen. Die Suche erfolgte in folgenden Datenbanken bzw. Internetseiten\nfolgender Organisationen: The Cochrane Library (Cochrane Database of Systematic Reviews, Health\nTechnology Assessment Database), MEDLINE (PubMed), AWMF, Clinical Evidence, CCO, DAHTA,\nESMO, G-BA, GIN, IQWiG, NCCN, NCI, NGC, NICE, TRIP, SIGN, WHO. Ergänzend erfolgte eine\nfreie Internetsuche nach aktuellen deutschen und europäischen Leitlinien. Die detaillierte Darstellung\nder Suchstrategie ist am Ende der Synopse aufgeführt.\nDie Recherche ergab 1421 Quellen, die anschließend in einem zweistufigen Screening-Verfahren\nnach Themenrelevanz und methodischer Qualität gesichtet wurden. Zudem wurde eine\nSprachrestriktion auf deutsche und englische Quellen vorgenommen. Insgesamt ergab dies 27\nQuellen, die in die synoptische Evidenz-Übersicht aufgenommen wurden.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "Indikation:",
      "text": "Zur Behandlung des Leberzellkarzinoms\nAbkürzu\nAkdae\nAWMF\nÄZQ\nCASP\nCCO\nDAHTA\nDCR\nDRKS\nESMO\nG-BA\nGIN\nHCC\nHFSR\nICTRP\nIQWiG\nISRCT\nMPV\nNCCN\nNCI\nNGC\nNHS C\nNICE\nOS\nPEI/PA\nPVB\nRFA\nSIGN\nTACE\nTAE\nTRIP\nTTP\nTTSP\nWHO\nungen\ne\nF\nA\nO\nP\nG\nTN\nN\nCRD\nAI\nn:\nArzneimittelkommission der deutschen Ärzteschaf\nArbeitsgemeinschaft der wissenschaftlichen mediz\nFachgesellschaften\nÄrztliches Zentrum für Qualität in der Medizin\nCritical Appraisal Skills Programme\nCancer Care Ontario\nDeutsche Agentur für Health Technology Assessm\ndisease control rate\nDeutsches Register Klinischer Studien\nEuropean Society for Medical Oncology\nGemeinsamer Bundesausschuss\nGuidelines International Network\nhepatozelluläres Karzinom\nhand and foot skin reactions\nInternational Clinical Trials Registry Platform\nInstitut für Qualität und Wirtschaftlichkeit im Gesun\nInternational Standard Randomised Controlled Tri\nmain portal vein\nNational Comprehensive Cancer Network\nNational Cancer Institute\nNational Guideline Clearinghouse\nNational Health Services Center for Reviews and D\nNational Institute for Health and Care Excellence\nOverall survival\npercutaneous ethanol injection /percutaneous ace\nportal vein branches\nradiofrequency ablation\nScottish Intercollegiate Guidelines Network\nTransarterial chemoembolization\nTransarterial embolization\nTurn Research into Practice Database\nTime to progression\ntime to symptomatic progression\nWorld Health Organization\nft\nzinisc\nment\nndhei\nial Nu\nDisse\netic ac\nchen\nitswes\number\nemina\ncid inj\nsen\nr\nation\njection\nn\nG-BA, 2015 [5].\nBeschluss\ndes Gemeinsame\nBundesausschuss\nüber eine Änderun\ndes Beschlusses\nüber Maßnahmen\nzur\nQualitätssicherung\nbei\nProtonentherapie\nbei Patientinnen u\nPatienten mit\ninoperablem\nhepatozellulärem\nKarzinom (HCC):\nVerlängerung der\nGültigkeitsdauer\nSiehe auch: G-BA\nIQ\nFazit: ,,D\nbeim inop\nQualitätss\nen\nmit inoper\nses\nng\nn\ng\nund\nA,\nQWiG\nDie Au\nperab\nsicher\nrablem\nG-Ber\nussetz\nlen H\nrung\nm HC\nrichte/G-BA-B\nzung des Bewer\nHCC und der Be\nder Protonenthe\nCC werden bis z\nBesch\nrtung\neschlu\nherapi\nzum 3\nhlüsse\ngsverfahren\nuss über M\nie bei Patie\n31. Dezem\nns zur Protonen\nMaßnahmen zur\nentinnen und Pa\nmber 2020 verlän\nnthera\nr\natient\nngert.\napie\nten\nRoccar\nal., 201\nManage\npeople w\ninterme\nstage\nhepatoc\ncarcinom\nrina D\nemen\nwith\nediate-\ncellula\nma\nD et\nnt of\nar",
      "start_page": 5,
      "end_page": 8
    },
    {
      "heading": "Cochrane Reviews",
      "text": "1. Fragestellung\nTo assess the comparative benefits and harms of different interventions\nin the treatment of intermediate-stage hepatocellular carcinoma (BCLC s\nB) through a network meta-analysis and to generate rankings of the ava\ninterventions according to their safety and efficacy.\nPopulation: Participants with intermediate-stage hepatocellular carcin\n(BCLC stage B) irrespective of the presence of cirrhosis, size and num\nof the tumours (provided they met the criteria of intermediate-stage\nhepatocellular carcinoma), presence or absence of portal hypertensio\naetiology of hepatocellular carcinoma, and the future remnant liver\nvolume. Randomised clinical trials in which participants had undergon\nliver transplantation previously were excluded.\nIntervention / Komparator: The following interventions that are possib\ntreatments for intermediate-stage hepatocellular carcinoma\neither alone or in combination tested versus each other, or versus pla\nor sham, or no intervention (supportive care) were condisered:\n• liver resection;\n• liver transplantation;\n• radiofrequency ablation;\n• microwave ablation;\n• other ablations (laser ablation, cryoablation, HIFU, irreversible\nelectroporation);\n• alcohol injection;\n• acetic acid injection;\n• radiotherapy (stereotactic body radiotherapy or radioembolisation);\n• systemic chemotherapy;\n• TAE;\n• TACE;\n• supportive care.\nEndpunkte: Mortality, Adverse events, Quality of Life, Disease recurre\nLength of hospital stay and complications\nSuchzeitraum (Aktualität der Recherche): The Cochrane Central Reg\nof Controlled Trials (CENTRAL), MEDLINE, Embase, Science Citatio\nIndex Expanded, World Health Organization International Clinical Tria\nRegistry Platform, and randomised clinical trials registers to Septemb\n2016 were searched.\nHinweis: We found only one comparison. Therefore, we did not perfo\nthe network meta-analysis\nAnzahl eingeschlossene Studien/Patienten (Gesamt): 3 trials with 43\nparticipants. All three trials included supportive care (treatment to pre\ncontrol, or relieve complications and side effects and improve comfor\nquality of life) as a co-intervention. The trials assessed transarterial\nused\nstage\nailable\nnoma\nmber\non,\nne\nble\nacebo\nence,\ngister\non\nals\nber\norm\nevent,\nrt and\nd\ne\ne\nr\no\nd\nSilva JP\nTransar\nchemoe\nn in hep\nP et a\nrterial\nembol\npatoce\nal.,\nl\nlizatio\nellula\nchemoembolisation (where anti-cancer drugs block the blood supply and\ntreat the cancer through the vessels supplying the cancer), chemotherapy\nusing sorafenib (a drug which blocks cancer growth), or a combination of\ntransarterial chemoembolisation and sorafenib.\nQualitätsbewertung der Studien: Cochrane risk of bias / GRADE",
      "start_page": 8,
      "end_page": 9
    },
    {
      "heading": "3. Ergebnisdarstellung",
      "text": "Qualität der Studien: The overall quality of evidence was low or very low and\nall the trials were at high risk of bias.\n• Over 18 to 30 months, 50% to 75% of participants died. There was no\nevidence of any difference between the people who received\nchemotherapy and those who did not receive chemotherapy.\n• None of the trials reported complications, health-related quality of life (a\nmeasure of a person’s satisfaction with their life and health), cancer\nrecurrence, or length of hospital stay.\n• Overall, there is currently no evidence for benefit of any active treatment\nin addition to supportive treatment for intermediate-stage hepatocellular\ncarcinoma. There is significant uncertainty on this and further high-quality\nrandomised clinical trials are required.\n4. Fazit der Autoren: This review included only trial participants with\nintermediate stage hepatocellular carcinoma (i.e. BCLCB stage; i.e. large,\nmultinodular, Child-Pugh status A to B, and performance status 0).\nTherefore, this review is applicable only to people with intermediate-stage\nhepatocellular carcinoma. It included a mixture of viral and non-viral\naetiologies and people with cirrhotic and non-cirrhotic livers. Hence, the\nreview is applicable to viral or non-viral aetiologies and people with\ncirrhotic and non-cirrhotic livers. None of the trials reported the proportion\nof people with portal hypertension. Therefore, it is not clear whether the\nfindings of the review are applicable in people with portal hypertension.\n5. Kommentar zum Review\n• Two trials were funded by the pharmaceutical industry; one trial did not\nreport the source of funding.",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "Systematische Reviews",
      "text": "1. Fragestellung\nThis systematic review sought to examine the role of TACE in the treatment\nof HCC with PVT in either the main portal vein (MPV) or portal vein branches\no (PVB).\nar\ny\ny\ns\ncarcinom\nportal ve\nthrombo\nsystema\nand me\nvan Ro\nBV et a\nSystem\nof trans\nemboliz\nhepatoc\nma with\nein tumor\nosis: a\natic review\neta-analysis\nosmalen",
      "start_page": 9,
      "end_page": 10
    },
    {
      "heading": "al., 2017",
      "text": "atic review\nsarterial\nzation for\ncellular\nPopulation: HCC patients with PVT.\nIntervention / Komparator: comparing TACE to another treatment for\nw\nmanagement of HCC with PVT\ns\nEndpunkte: overall survival (OS), mRECIST response, and complication\nincidence\nSuchzeitraum (Aktualität der Recherche): PubMed was searched from\nJanuary 1, 2006 to August 31, 2016.\nAnzahl eingeschlossene Studien/Patienten (Gesamt): 13 studies with\n1933 TACE patients were included.\nQualitätsbewertung der Studien: Newcastle–Ottawa Scale",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "3. Ergebnisdarstellung",
      "text": "Qualität der Studien: Several of the studies were non-randomized or\nretrospective, allowing for patient selection bias to influence the results (keine\nweiteren Angaben im Text)\n• Median OS (95% CI) was eight (5–15) months. Survival rates after one,\nthree, and five years were 29% (20%–40%), 4% (1%–11%), and 1%\n(0%–5%), respectively.\n• Only 1% experienced liver failure and 18% had post-treatment\ncomplications.\n• Patients with MPV thrombosis had worse survival than PVB patients (p <\n0.001), but similar mRECIST response rates (14% vs. 16%).\n4. Fazit der Autoren: TACE is a safe treatment for a highly selected\npopulation of HCC patients with PVT. Despite worse survival rates\ncompared to PVB thrombosis, PVT in the MPV should not be considered\nan absolute contraindication to TACE.\n5. Kommentar zum Review:\n• All studies were from Asian countries, with eight from China, one from\nJapan, three from Korea, and one from Taiwan.\n• heterogeneity between the studies\n1. Fragestellung\nThis systematic review provides an overview of clinical outcomes after TAE,\nin bleeding and non-bleeding HCA.\nw\nPopulation: patients with HCA\nIntervention/Komparator: TAE techniques\ne\nd\nade\ndenom\nmas\nHinweis: Studies considering hepatic malignancies and tumours other than\nHCA, those reporting techniques other than TAE (such as radiofrequency\nablation or hepatic artery ligation) and reviews were excluded.\nEndpunkte: tumour size, malignant transformation or adverse events.\nSuchzeitraum (Aktualität der Recherche): systematic literature search, up\nto 7 January 2016, of the PubMed and Embase databases was\nundertaken\nAnzahl eingeschlossene Studien/Patienten (Gesamt): 40 articles included",
      "start_page": 10,
      "end_page": 11
    },
    {
      "heading": "a total of 851 patients (20 cohort studies and 20 case reports), of whom",
      "text": "151 (17,7 %) underwent TAE for 196 lesions.\nQualitätsbewertung der Studien: To assess the quality of the selected\nstudies, the Critical Appraisal Skills Programme (CASP) for cohort studies\nwas used. Three items (what are the results of this study, how precise are\nthe results and what are the implications of this study for practice?) of the\nCASP tool were left out of the critical appraisal. Regarding point 6 of the\nCASP tool, a follow-up of at least 12 months was considered appropriate\nto judge the effect on tumour size. The quality of case reports was not\nassessed because of likely selection bias. The Oxford Centre for\nEvidence-Based Medicine Levels of Evidence were determined for all\nstudies, where level 1 is the highest level of evidence, and level 5 the\nlowest.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "Qualität der Studien: Among the 20 studies, 18 were considered to provide",
      "text": "level 2b evidence and two level 1b. Seven cohort studies scored ‘yes’ on all\n11 items of the CASP tool. All case reports were considered as level 4\nevidence.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "• Surgical treatment was avoided in 68 of 151 patients (45.0%). Elective",
      "text": "TAE was performed in 49 patients involving 66 HCAs, with 41 of these",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "patients (84%) not requiring surgery.",
      "text": "• Major complications occurred in eight of 151 patients (5,3%); no death\nwas reported.\n• Among cohort studies, complete tumour disappearance was observed in\n10% of patients, and regression in 75%.\n4. Fazit der Autoren: Acute or elective TAE in the management of HCA\nseems safe. TAE in the elective setting offers a reasonable alternative to\nsurgery, considering its minimally invasive and parenchyma-sparing\nproperties, and the ability to reduce the size of tumours situated in a\ndifficult anatomical position for surgery. Its influence on symptoms and\nwhether it modifies risks of neoplastic regression remain unknown.\n5. Kommentar zum Review:\n• Ausschließlich Kohortenstudien und Fallserien\nn\ns\ne\no\nFaccior\nal., 201\nTransar\nchemoe\nn vs bla\nemboliz\nhepatoc\ncarcinom\nmeta-an\nrandom\nrusso A et\nrterial\nembolizatio\nand\nzation in\ncellular\nma: A\nnalysis of\nmized trials\nt 1. Fragestellung\nThe objective of this article is to systematically analyze the results provided\nby randomized controlled trials comparing these two treatments in\no hepatocarcinoma patients.\nPopulation: hepatocarcinoma patients\nIntervention / Komparator: TACE vs. TAE\nEndpunkte: Survival rates assessed at one, two, and three years,\nobjective response, one-year progression-free survival, and severe\nadverse event rate\nSuchzeitraum (Aktualität der Recherche): PubMed/Medline, Embase,\nGoogle Scholar, and Cochrane library databases were searched until\nFebruary 2016.\nAnzahl eingeschlossene Studien/Patienten (Gesamt): 6 RCTs with 676\npatients (342 treated with TACE and 334 with TAE) were included in the\nmeta-analysis.\nQualitätsbewertung der Studien: Cochrane Collaboration’s tool.\nComparisons were performed by using the Mantel-Haenszel test in cases\nof low heterogeneity or DerSimonian and Laird test in cases of high\nheterogeneity.",
      "start_page": 11,
      "end_page": 12
    },
    {
      "heading": "3. Ergebnisdarstellung",
      "text": "Qualität der Studien: Three RCTs were considered high quality and three\nmoderate quality.",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "• No difference in one-year (risk ratio: 0.93, 0.85–1.03, p=0.16), two-year",
      "text": "and three-year survival was observed.\n• Objective response and one-year progression-free survival showed no\nsignificant difference between the two treatments.\n• A statistically significant increase in severe toxicity after",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "chemoembolization was found (risk ratio: 1.44, 1.08–1.92, p=0.01),",
      "text": "although this result could be affected by the heterogeneity of techniques\nadopted.\n4. Fazit der Autoren: In conclusion, despite these weaknesses, our meta-\nanalysis supports the non-superiority of TACE with respect to TAE, which\nin turn appears even safer particularly when compared to conventional\nchemoembolization. These conclusions need to be confirmed in broad\nnon-inferiority trials with a large number of cases, strict selection of\npatients in terms of tumour burden, severity of liver dysfunction (as this\nstrongly affects OS) as well as comorbidities (as these as well affect\nsurvival) and standardized modality of endovascular tumour treatment\nh\nWang X et al.,\nEfficacy and\nSafety of\nRadiofrequency\nAblation\nCombined with\nTranscatheter\nArterial\nChemoembolizati\non for\nHepatocellular\nCarcinomas\nCompared with\nRadiofrequency\nAblation Alone: A\nTime-to-Event\nMeta-Analysis\nSiehe auch:\nWang Y et al.,",
      "start_page": 12,
      "end_page": 13
    },
    {
      "heading": "2016 [23]; Kong",
      "text": "QF et al., 2014\n[8]; Ni JY et al.,",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "2013 [15]; Liu Z",
      "text": "et al., 2014 [12];\nCao JH et al.,",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "2014 [3]; Huo YR",
      "text": "and reporting of adverse events.22 In the lack of a better source of\nevidence, the present meta-analysis appears to provide the most\npossible solid information on the comparison of TACE with TAE.\n1. Fragestellung\nTo compare the efficacy and safety of combined radiofrequency ablation\n(RFA) and transcatheter arterial chemoembolization (TACE) with RFA alone\nfor hepatocellular carcinomas (HCC).\nPopulation: Patients with HCC\nIntervention / Komparator: combination therapy of TACE and RFA versus\ni RFA monotherapy\nEndpunkte: Overall survival, recurrence-free survival,\nmajor complications\nSuchzeitraum (Aktualität der Recherche): Pubmed, Embase, Cochrane\nLibrary, Chinese Biomedical Database (CBM), CNKI, and Google Schola\nA\nfrom their inception years to February 13, 2015\nAnzahl eingeschlossene Studien/Patienten (Gesamt): 6 RCTs (16, 23-27\npublished between 2005 and 2013 with 534 patients were analyzed in th\nmeta-analysis.\nQualitätsbewertung der Studien: Risk of bias tool suggested by the\nCochrane Handbook for Systematic Reviews of Interventions. In addition\nto evaluate the quality of evidence from the pooled results, the Grading o\nRecommendations Assessment, Development, and Evaluation system\n(GRADE system) was employed.\n; 3. Ergebnisdarstellung\nQualität der Studien:\nR\ne\ns\nar\nhis\nn,\nof",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "et al., 2015 [7].",
      "text": "Li J et al., 2017\nTranscatheter\nhepatic arterial\nchemoembolizatio\nn and sorafenib\nfor hepatocellular\ncarcinoma: a\nmeta-analysis of\nrandomized,\ndouble-blind\ncontrolled trials.\nSiehe auch: Zeng\nJ et al., 2016\n• The meta-analysis showed that the combination of TACE and RFA is\nassociated with a significantly longer overall survival (HR = 0.62, 95% CI:\n0.49–0.78, p < 0.001) and recurrence-free survival (HR = 0.55, 95% CI:\n0.40–0.76, p < 0.001) in contrast with RFA monotherapy.\n• The seemingly higher incidence of major complications in the\ncombination group compared with RFA group did not reach statistical\nsignificance.\n4. Fazit der Autoren: In conclusion, this meta-analysis suggested that the\ncombination of TACE and RFA is associated with significantly higher\noverall survival and recurrence-free survival than RFA monotherapy in the\npatients with HCC without significant difference in major complication\nbetween them. These results need to be validated in RCTs with better\nquality and larger sample sizes.\n1. Fragestellung\nA meta-analysis of transcatheter hepatic arterial chemoembolization (TACE)\ncombined with sorafenib for hepatocellular carcinoma (HCC)\no\nPopulation: Patients with HCC. Patients were not suitable candidates for\nr\nsurgical resection; participants were 18 years of age or older.\nIntervention: TACE + sorafenib\nKomparator: Placebo\nEndpunkte: TTP or overall survival (OS); and reported adverse events\nSuchzeitraum (Aktualität der Recherche): MEDLINE, EMBASE, EBSCO,\ng\nSpringer, Ovid, and Cochrane Library databases search ending in 2016.\nAnzahl eingeschlossene Studien/Patienten (Gesamt): 4 placebo-controlled\nRCTs were included in the meta-analysis with a total of 877 HCC cases\nfrom 14 countries, including China and the USA.\nQualitätsbewertung der Studien: Quality assessment was performed\nbased on the following criteria: Allocation was sufficiently randomized;\nblinding for allocation was sufficient; blinding for the intervention was\nsufficient; and loss to follow-up or exit status were evaluated.",
      "start_page": 14,
      "end_page": 15
    },
    {
      "heading": "3. Ergebnisdarstellung",
      "text": "Qualität der Studien: The various studies used different methods of\nrandomization for allocation to the experimental and control groups. Blinding\nand randomization were determined to be adequate in all of the selected\nRCTs, whereas only one of these studies adequately described allocation\nconcealment. The risks of selection, performance, or detection biases were\nnot quantified in any of the included studies.\n• The TTP increased significantly in the experimental groups (hazard ratio\n[HR]: 0.82; 95% CI: 0.69–0.97; p = 0.02), but OS did not improve\nsignificantly, compared with the control groups.\n• The risks of hand and foot skin reactions (HFSR), rash, fatigue, and\ndiarrhea were significantly greater in the experimental groups (p < 0.05\nfor all), compared to those in the control groups, whereas the risk of\nnausea was statistically similar. Among these, the risk of HFSR was\nhighest (risk ratio [RR]: 5.93; 95% CI: 2.00–17.53; p = 0.001), and a\nsubgroup analysis of studies that lacked significant heterogeneity in the\nHFSR data showed a higher risk of HFSR (RR: 10.96; 95% CI: 5.54–\n21.69; p < 0.05).\n4. Fazit der Autoren: In conclusion, although TACE plus sorafenib increases\nTTP in patients with HCC, it does not improve OS. Therefore, the\nincreased risk of adverse events in patients receiving TACE plus sorafen\nsuggests that this combination therapy might not represent an\nimprovement over treatment with TACE alone. The relatively small numb\nof RCTs that met the selection criteria for our meta-analysis demonstrate\nthe need for uniform application of clinical outcome indicators to facilitate\nfuture comparisons of studies of TACE plus sorafenib for the treatment o\nHCC.\n5. Kommentar zum Review:\n• (…) We did not assess statistical power for our analysis, but the relative\nsmall number of RCTs included in our meta-analysis represents a\npotential confounder of our findings.\n• (…) The small number of selected RCTs also precluded the use of funn\nplots to assess whether publication bias influenced our findings, but the\nrandomization and double blinding performed in all of the RCTs include\nin our meta-analysis likely minimized the potential effects of selection,\nperformance, and detection biases.\ng\non\ne\ns\nnib\nber\ne\ne\nof\nely\nnel\ne\ned\nWang G et al.,\nSorafenib\ncombined with\ntransarterial\nchemoembolizatio\nn in patients with\nhepatocellular\ncarcinoma: a\nmeta-analysis and\nsystematic\nreview.\nSiehe auch:\nZhang L et al.,\n1. Fragestellung\nThis study evaluated the efficacy and safety of TACE + sorafenib.\nPopulation: patients with advanced HCC\no\nIntervention/Komparator: TACE vs. TACE + Sorafenib\nEndpunkte: The primary outcome measure was time to progression (TTP),\nand the secondary outcomes measures were overall survival (OS) and\nd\nadverse events.\nSuchzeitraum (Aktualität der Recherche): MEDLINE, the Cochrane\nLibrary, EMBASE, and the ISI Web of Knowledge were searched until 31",
      "start_page": 15,
      "end_page": 16
    },
    {
      "heading": "December 2013.",
      "text": "Anzahl eingeschlossene Studien/Patienten (Gesamt): Five comparative\nstudies (2 were randomized control trials) that included 899 patients\nQualitätsbewertung der Studien: The Delphi list was used to assess the\nquality of the randomized controlled trials. The Newcastle-Ottawa scale\nwas used to assess the quality of the nonrandomized controlled study.",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "3. Ergebnisdarstellung",
      "text": "Qualität der Studien: The quality of the data was evaluated for the two\nincluded studies that were randomized control trials using the Delphi list. The\nstudy of Kudo et al. received 8 points and of Sansonno et al. 7 points,\nindicating the data were of good quality. A risk for detection bias was present\nbecause the outcome assessors in both studies were not blinded. The\nSansonno et al. study also did not include an intention-to-treat analysis. The\nquality of the Bai et al., Muhammad et al. and Qu et al. studies, which were\nnon-randomized, was evaluated using the Newcastle-Ottawa scale. The Bai\net al. data were considered of high quality as they received a score of 9.\nMuhammad et al. and Qu et al. received a score of 6 because they may have\nhad selection bias as they did not explain the selection of participants.\n• Patients treated with TACE + sorafenib had better prognoses in terms of\ntime to progression (TTP) compared to those with TACE + placebo or\nTACE alone; hazard ratios (HRs) ranged from 0.40 to 0.87, with the\ncombined HR 0.61 (95 % CI 0.39–0.95, p = 0.031).\n• However, the combined HR for overall survival (OS) did not differ\nsignificantly between patients treated with TACE + sorafenib and those\nwith TACE + placebo or TACE alone.\n• Sensitivity analysis indicated the findings for TTP may be overly\ninfluenced by at least one of the studies.\n4. Fazit der Autoren: In summary, our meta-analysis found that TACE +\nsorafenib can improve TTP. We did not find the combined therapy\nWang Z et al.,\nMeta-analysis of\nthe Efficacy of\nSorafenib for\nHepatocellular\nCarcinoma\nimproved OS. Additional randomized controlled studies are necessary t\nfurther investigate the clinical benefit of TACE + sorafenib in treating\nadvanced HCC\n1. Fragestellung\nBy carrying out a meta-analysis of randomized controlled trials that compare\nsorafenib or combined chemotherapy with placebo or combined\nchemotherapy, the effectiveness of sorafenib in hepatocellular carcinoma\nwas evaluated in the present study, which also provided clinical practice\nguidelines of evidence-based-medicine.\nPopulation: hepatocellular carcinoma patients\nIntervention: Sorafenib\nKomparator: Placebo\nEndpunkte: Overall survival (OS), time to progression (TTP), time to\nsymptomatic progression (TTSP), disease control rate (DCR) and advers\nreactions\nSuchzeitraum (Aktualität der Recherche): Review of PubMed citations\nconcerning sorafenib treating hepatocellular carcinoma in randomized\ncontrolled trials from Jan 2000 to July 2012\nAnzahl eingeschlossene Studien/Patienten (Gesamt): Finally, four paper\ndocumenting randomized controlled studies were included\nQualitätsbewertung der Studien: RCT bias risk assessment methods in\nCochrane handbook",
      "start_page": 16,
      "end_page": 17
    },
    {
      "heading": "3. Ergebnisdarstellung",
      "text": "Qualität der Studien: All trials included in this analysis were double-blind\nplacebo-controlled randomized phase 3 clinical trials.\nEfficacy:\nCompared with controls, sorafenib was shown to significantly increase over\nsurvival (OS), time to progression (TTP), and disease control rates (DCR),\nbut not the time to symptom progression (TTSP) in hepatocellular carcinom\npatients.\nto\ned\nse\ns\nrall\nma\nBelinso\nLocal T\nfor Unre\nPrimary\nHepatoc\nCarcino\non S e\nherap\nesecta\ny\ncellul\noma\net al.\npies\nable\nlar\nAdverse events:\nThe incidence of grade-III/IV adverse reactions, including hand-foot-sk\nreactions, diarrhea, hypertension and skin rash or desquamation, in so\ntreatment group was higher than that in controls.\nHowever, there was no significant difference in the incidence of hypody\nbetween the two groups.\n4. Fazit der Autoren: Sorafenib exerts significant curative effects in\nhepatocellular carcinoma.\n., 1. Fragestellung\nTo characterize the comparative effectiveness and harms of various loc\nhepatic therapies for patients with unresectable primary hepatocellular\ncarcinoma (HCC) who are not candidates for surgical resection or liver\ntransplantation. Local hepatic therapies include those related to ablatio\nembolization, and radiotherapy.\nKQ1. What is the comparative effectiveness of the various liver-directe\ntherapies in patients with HCC who are not otherwise candidates for su\nresection or transplantation with no evidence of extrahepatic disease\nregarding survival and quality of life?\nKQ2. What are the comparative harms of the various liver-directed the\nin patients with HCC who are not otherwise candidates for surgical res\nor transplantation with no evidence of extrahepatic disease regarding\nadverse events?\nKQ3. Are there differences in comparative effectiveness of various live\ndirected therapies in patients with HCC who are not otherwise candida\nsurgical resection or transplantation for specific patient and tumour\ncharacteristics, such as age, gender, disease etiology, and Child-Pugh\nscore?\nPopulation: HCC in patients who meet all of the following criteria:\n• No extrahepatic spread\n• No portal invasion\nkin\norafen\nynam\ncal\nr\non,\ned\nurgica\nerapie\nsection\ner-\nates fo\nh\nnib\nmia\nal\nes\nn\nor\n• Child-Pugh class A or B disease\n• Eastern Cooperative Oncology Group (ECOG) status ≤1\nand/or\n• BCLC stage A or B, or equivalent\nIntervention / Komparator: Local therapies (siehe Ergebnisteil)\nEndpunkte: overall survival and quality of life—and various adverse event\nSuchzeitraum (Aktualität der Recherche): MEDLINE and Embase from\nJanuary 2000 to July 2012\nAnzahl eingeschlossene Studien/Patienten (Gesamt): Siehe Ergebnisteil!\nQualitätsbewertung der Studien: In the assessment of risk of bias in\nindividual studies, we followed the Agency for Healthcare Research and\nQuality (AHRQ) “Methods Guide for Effectiveness and Comparative\nEffectiveness Reviews” (Methods Guide) / GRADE\n3. Ergebnisdarstellung\nQualität der Studien: Siehe Ergebnisteil\nOverall Conclusions for Key Questions 1–3\n• Six RCTs, four nonrandomized comparative studies, 35 case series, and\nthree case reports comprised the body of literature. One RCT was rated\nas good, three were rated as fair and two were rated as poor quality.\n• The body of evidence for RFA compared with PEI/PAI was rated\nmoderate strength to support better overall survival at 3 years for RFA\ncompared with PEI/PAI with a low risk of bias.\n• The body of evidence for RFA compared with PEI/PAI was rated low\nstrength to support increased TTP, improved local control, and a longer\nLOS for RFA compared with PEI/PAI, with a high risk of bias.\n• For all other comparisons, the body of evidence on overall survival,\nquality of life, disease progression, local control, LOS, days of missed\nwork, and adverse events for local hepatic therapy for the treatment HCC\nis insufficient to support the effectiveness of one local hepatic therapy\nover another, due to the lack of comparative studies.\n• Studies with subgroup analyses were limited to the three studies\nreporting on the comparison of RFA to PEI/PAI. These analyses\nreviewed Child-Pugh class, lesion size, and multifocal disease for their\neffects on overall survival, but were not pre-specified. Lesion size was\nalso examined by Lin et al 2004 for its effects on cancer-free survival an\nlocal recurrence. There is a low strength of evidence to support increase\noverall survival for RFA compared with PEI/PAI in patients with larger\nlesions with a high risk of bias. The evidence is insufficient to assess the\neffects lesion size on other outcomes of interest in this report and of othe\npatient subgroups on any outcome of interest in this report.\n• The assessment of applicability of the study findings to clinical practice is\nlimited by the poor characterization of the patient populations (e.g.,\nnumber and size of metastases, performance status) and variations in\nthe delivery of the interventions (e.g., surgical approach and dose and\ndrugs delivered).\nts\nd\nd\nC\nnd\ned\ne\ner\ns\nPeng S et al.,\nAn Updated Meta\nAnalysis of\nRandomized\nControlled Trials\nAssessing the\nEffect of\nSorafenib in\nAdvanced\nHepatocellular\nCarcinoma.\n4. Fazit der Autoren: (…) For the comparison of RFA to PEI/PAI, our\nconclusions suggest that for these patients treatment with RFA confers a\nsurvival benefit at 3 years compared with PEI/PAI. In addition, TTP and\nlocal recurrence may be improved in patients treated with RFA compared\nwith PEI/PAI. Patients treated with RFA also seem to have longer LOS\nafter treatment compared with those treated with PEI/PAI. Beyond this\nevidence on the comparative effectiveness of these procedures was\ninsufficient. Subsequent comparisons had only one or no comparative\nstudies on a given treatment comparison. For these comparisons,\nevidence was insufficient for all outcomes; thus, there is no comparative\nevidence base to support decision making. In cases where comparative\nevidence existed, data were judged to be insufficient due to high risk of\nbias and/or imprecision of estimates.\n1. Fragestellung\nThe efficacy of sorafenib in the treatment of advanced hepatocellular\na- carcinoma (HCC) remains controversial. Therefore, we conducted a meta-\nanalysis to evaluate the efficacy and safety of sorafenib for treating patients\nwith advanced HCC.\nPopulation: adult patients with advanced (unresectable or metastatic) HCC\nIntervention: sorafenib or sorafenib-based therapy\nKomparator: placebo or placebo-based (without sorafenib) therapy\nEndpunkte: primary: overall survival (OS); secondary: time to progression\n(TTP), overall response rate (ORR), and toxicity\nSuchzeitraum (Aktualität der Recherche): bis 03/2014\nAnzahl eingeschlossene Studien/Patienten (Gesamt): 7 (n=3807)\nQualitätsbewertung der Studien: The methodological quality of each study\nwas assessed with the Jadad scale.\n3. Ergebnisdarstellung\nQualität der Studien: In the present meta-analysis, all included studies were\nwell-designed and of high quality (Jadad score range from 4 to 5).\nOverall survival (n=7 studies):\n• sorafenib was associated with a significant improvement in OS\n• (HR=0.74, 95% CI: 0.61, 0.90; P=0.002)\n• heterogeneity was significant (P=0.000, I2=77.0%)\n• Subgroup analysis: sorafenib was an effective treatment for patients with\nECOG PS of 1–2 (HR=0.77, 95% CI: 0.60, 1.0; P=0.05), or macroscopic\nvascular invasion (MVI) and/or extrahepatic spread (EHS) (HR=0.65,\n95% CI: 0.46, 0.93; P=0.02)\n• Begg and Egger tests provided no evidence of publication bias\nXie ZB\nTransar\nemboliz\nor witho\nchemot\nadvance\nhepatoc\ncarcinom\nsystema\nreview.\net al.\nrterial\nzation\nout\ntherap\ned\ncellula\nma: a\natic\nl\nn with\npy for\nar\na\nTime to progression (n=6 studies):\n• TTP benefit existed in the sorafenib group when compared with the\ncontrol group (HR=0.69, 95% CI: 0.55, 0.86; P=0.001)\n• heterogeneity was significant (P=0.000, I2=84.4%)\n• Subgroup analysis: significant TTP benefits of sorafenib treatment in the\npatients irrespective of MVI, EHS, and ECOG status\n• Begg and Egger tests provided no evidence of publication bias\nOverall response rate (n=5 studies):\n• sorafenib did not have a higher ORR when compared with other\ntreatments (RR=0.85, 95% CI: 0.65, 1.11; P=0.10)\n• Begg and Egger tests provided no evidence of publication bias\nAdverse events (n=5 studies):\n• Sorafenib induced a significantly higher rate of hand-foot syndrome\n(RR=5.4, 95% CI: 1.8, 16.2; P=0.003), diarrhea (RR=1.45, 95% CI: 1.21,\n2.34; P=0.003), fatigue (RR=1.70, 95% CI: 1.30, 2.23; P=0.000), and\nrash (RR=3.21, 95% CI: 1.65, 6.26; P=0.001)\n4. Fazit der Autoren: Treatment with sorafenib significantly improved OS and\nTTP in patients with advanced HCC. Additional large-scale, well-designed\nRCTs are needed to evaluate the efficacy of sorafenib-based therapy in\nthe treatment of advanced HCC.\n1. Fragestellung\nWe investigated the efficacy and safety of TACE with or without\nchemotherapy in patients with advanced HCC.\nh 2. Methodik\nr\nPopulation: patients with advanced HCC\nIntervention: arterial embolization with an antitumor drug (any type of\nembolization material or antitumor drug)\nKomparator: arterial embolization\nEndpunkte: primary: all-cause mortality (all-cause mortality defined as\ndeath due to any cause) or overall survival (OS); secondary: tumor\nresponse rate, adverse events, quality of life, liver function, and tumor\nreduction\nSuchzeitraum (Aktualität der Recherche): bis 04/2014\nAnzahl eingeschlossene Studien/Patienten (Gesamt): 5 (n=582)\nQualitätsbewertung der Studien: Two reviewers independently assessed\nthe risk of bias for each study using the criteria outlined in the Cochrane\nHandbook for Systematic Reviews of Interventions.\n3. Ergebnisdarstellung\nQualität der Studien:\nRisk of bias summary:\nShen A et al.,\nA systematic\nReview of\nSorafenib in\nChild-Pugh A\nPatients\nAll-cause mortality (n=5 studies):\n• no significant effect of all-cause mortality (RR=1.21, 95 % CI=0.74–\n1.98, P=0.16)\nSurvival (n=5 studies):\n• 1-year survival did not differ between TACE and TAE (RR=0.92, 95 %\nCI=0.83–1.01, P=0.53)\nTumor response rates(n=1 study)\n• No significant difference were observed between TACE and TAE\nAdverse events (n=k. A.)\n• The most common adverse events were post-TACE syndromes (pain,\nfever, nausea, vomiting).\n• In the TACE group, the incidence of nausea and vomiting appeared to\nbe increased compared with the TAE group\n• In contrast to TAE, TACE was found to cause myelosuppression due to\nthe use of an antitumor drug.\nQuality of life (n=1 study)\n• None of the scores was significantly different between the two groups.\nTumor reduction (n=k. A.)\n• The difference between TACE group and TAE group was not significant\nin this outcome.\nLiver function (n=1 study)\n• No significant differences of liver function between the two groups was\nobserved (RR=1.17, 95 % CI=0.48–2.86, P=0.48).\n4. Fazit der Autoren: The efficacy of TACE is not superior to TAE in\nadvanced HCC patients. Moreover, TACE was associated with an\nincreased rate of adverse events than TAE. Improved strategies are\nneeded to reduce the risk of post-TACE complications.\n1. Fragestellung\nWe performed a systematic review of the efficacy and safety of sorafenib in\nChild-Pugh A patients with unresectable HCC. The value of sorafenib\ntreatment in different subgroups was examined.\nWith\nUnresec\nHepatoc\nCarcino\nctable\ncellul\noma.\ne\nlar\nPopulation: Child-Pugh A patients with unresectable HCC\nIntervention: sorafenib\nKomparator: placebo\nEndpunkte: disease control rate (DCR), time to progression (TTP), overall\nsurvival (OS), adverse events\nDefinition DCR: DCR was defined as the percentage of patients who had a\ncomplete response, a partial response or stable disease (according to\nRECIST) that was maintained for at least 28 days after the first\ndemonstration of that rating.",
      "start_page": 17,
      "end_page": 23
    },
    {
      "heading": "Suchzeitraum (Aktualität der Recherche): bis 07/2012",
      "text": "Anzahl eingeschlossene Studien/Patienten (Gesamt): 5 (n=1462)\nQualitätsbewertung der Studien: Two independent reviewers (A.S. and\nC.T.) evaluated the quality of each trial, according to the Cochrane\nHandbook for Systematic Reviews of Interventions.\n3. Ergebnisdarstellung\nQualität der Studien: Two of the studies were found to have a low risk of bias\nand 3 trials had a high risk of bias.\nDCR (n=3 studies):\n• Sorafenib group had an 85% higher response rate than the placebo",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "group (sorafenib vs. placebo, RR, 1.85; 95% CI, 1.55, 2.20; P<0.001;",
      "text": "I2=0.0%)\nTTP (n=5 studies):\n• sorafenib improved the TTP significantly over placebo (HR, 0.61; 95% CI,\n0.51, 0.73; P<0.001; I2=31.8%)\nOverall Survival (n=4 studies):\n• sorafenib treatment improved the survival of patients (HR, 0.71; 95% CI,\n0.56, 0.89; P<0.001; I2=46.5%)\nAdverse events (n=5 studies):\n• sorafenib increased the incidence of overall AEs, such as fatigue\n(21.4%), alopecia (24.5%), hand-foot skin reaction (HFSR; 33.2%), rash\nor desquamation (23.0%), diarrhea (29.8%), nausea (11.8%), and\nhypertension (14.9%)\n4. Fazit der Autoren: Sorafenib was a moderately effective and safe oral\ndrug for use in Child-Pugh A patients with unresectable HCC. Sorafenib\nmonotherapy is not recommended for treating intermediate-stage HCC.\nMore research is needed on the efficacy of sorafenib treatment in\npatients with prior local therapy.\nAlberta\nService\nHEPAT\nR CARC\na Hea\nes, 20\nTOCE\nCINO\nalth\nELLUL\nOMA",
      "start_page": 23,
      "end_page": 24
    },
    {
      "heading": "Leitlinien",
      "text": "GUIDELINE QUESTIONS\n1]. What are the goals of therapy and recommendations for the treatment of\nadult patients with:\nLA\n• intermediate stage hepatocellular carcinoma?\n• advanced stage hepatocellular carcinoma?\n• terminal stage hepatocellular carcinoma?\nGrundlage der Leitlinie\nThis guideline was developed to promote evidence-based practice in Alberta.\nIt was compiled from the results of randomized controlled trials and\nsystematic reviews, derived from an English language and relevant term\nsearch of PubMed and MEDLINE from 1990 forward. It takes into\nconsideration related information presented at local, national, and\ninternational meetings as well as the Alberta Provincial Gastrointestinal\nTumour Team’s interpretation of the data.\nSuchzeitraum: This guideline was developed to promote evidence-based\npractice in Alberta. It was compiled from the results of randomized controlled\ntrials and systematic reviews, derived from an English language and relevant\nterm search of PubMed and MEDLINE from 1990 forward. It takes into\nconsideration related information presented at local, national, and\ninternational meetings as well as the Alberta Provincial Gastrointestinal\nTumour Team’s interpretation of the data. The 2015 update did not\nnecessitate a full literature review; recommendations were modified based on\na consensus discussion at the 2014 Annual Gastrointestinal Tumour Team\nMeeting.\nLoE/GoR\nLevel Description of Evidence\n1a Systematic reviews of randomized controlled trials\n1b Individual randomized controlled trials\n1c All or none randomized controlled trials\n2a Systematic reviews of cohort studies\n2b Individual cohort study or low quality randomized controlled\ntrial\n2c Outcomes research\n3a Systematic review of case-control studies\n3b Individual case-control study\n4 Case series\n5 Expert opinion without explicit critical appraisal or based on\nphysiology, bench research, or “first principles”\nFreitext/Empfehlungen/Hinweise\nDKG, 2013 [9,10]\nDiagnostik und\n]. Fra\nEm\nMet\nageste\nmpfehl\nthodik\nellung/Zielsetzu\nlungen zur Diag\nk\nung:\ngnostik und The\nerapie des hepa\natoze\nelluläre\nen Karzinoms\nTherapi\nhepatoz\nKarzino\nie des\nzellulä\noms\ns\nären\nGrundlage der Leitlinie\nGrundlage der Leitlinie: Die Entwicklung der Leitlinie erfolgte in einem\nstrukturierten Prozess nach dem AWMF-Regelwerk\nAls Ausgangspunkt für\neine Literaturrecherche erfolgte im Vorfeld eine Gliederung der Leitlinie nach\nverschiedenen Themenkomplexen. Die Schlüsselfragen wurden im\ninterdisziplinären Konsensus auf dem ersten Arbeitstreffen (Kick-off-Meeting)\nidentifiziert. Um die Schlüsselfragen beantworten zu können, wurde ein\nKonzept zu ihrer gegenüberstellenden Darstellung mit den Aussagen\ninternationaler Leitlinien und der ihnen zugrundeliegenden Literatur\nentwickelt. In einem zweiten Treffen unter Beteiligung aller Mandatsträger der\nunterschiedlichen Fachgesellschaften und Institutionen wurde geklärt, auf\nwelcher Grundlage (De-Novo-Recherche, Leitlinienadaptation oder reiner\nExpertenkonsens) die Schlüsselfragen beantwortet werden sollen\nSuchzeitraum: Im Oktober 2009 und Januar 2010 erfolgte die zentrale und\nsystematische Suche nach Leitlinien für die Diagnostik und Therapie des\nhepatozellulären Karzinoms, die entweder auf Englisch oder Deutsch\nzwischen Januar 2000 bis November 2009 publiziert wurden.\n• Gültigkeit nach Überprüfung durch das LL-Sekretariat verlängert bis",
      "start_page": 24,
      "end_page": 26
    },
    {
      "heading": "Schema der Evidenzgraduierung nach Oxford",
      "text": "Zur Klassifikation des Verzerrungsrisikos der identifizierten Studien wurde in\ndieser Leitlinie das in Tabelle 7 aufgeführte System des Oxford Centre for\nEvidence-based Medicine in der Version von 2009 verwendet. Dieses System\nsieht die Klassifikation der Studien für verschiedene klinische Fragestellungen\n(Nutzen von Therapie, prognostische Aussagekraft, diagnostische Wertigkeit)\nvor.\nLoE/GoR",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "Schema der Empfehlungsgraduierung",
      "text": "Die OL-Methodik sieht eine Vergabe von Empfehlungsgraden durch die\nLeitlinien-Autoren im Rahmen eines formalen Konsensusverfahrens vor.\nDementsprechend wurde ein durch die AWMF moderierter, mehrteiliger\nnominaler Gruppenprozess durchgeführt. Am Ende dieses\nGruppenprozesses wurden die Empfehlungen von den stimmberechtigten\nMandatsträgern (siehe Kapitel 1.7) formal abgestimmt. Die Ergebnisse der\njeweiligen Abstimmungen sind entsprechend den Kategorien in Tabelle 9 den\nEmpfehlungen zugeordnet.\nIn der Leitlinie werden zu allen evidenzbasierten Statements (siehe Kapitel\n2.2.3) und Empfehlungen das Evidenzlevel (siehe 2.2.1) der\nzugrundeliegenden Studien sowie bei Empfehlungen zusätzlich die Stärke\nder Empfehlung (Empfehlungsgrad) ausgewiesen. Hinsichtlich der Stärke der\nEmpfehlung werden in dieser Leitlinie drei Empfehlungsgrade unterschieden\n(siehe Tabelle 8), die sich auch in der Formulierung der Empfehlungen\njeweils widerspiegeln.\nTabelle 8: Schema der Empfehlungsgraduierung\nEmpfehlungsgrad Beschreibung Syntax\nA Starke Empfehlung soll\nB Empfehlung sollte\nC Empfehlung offen kann\nTabelle 9: Konsensusstärke\nKonsenstärke Prozentuale Zustimmung\nStarker Konsens > 95% der Stimmberechtigten\nKonsens > 75 – 95% der Stimmberechtigten\nMehrheitliche Zustimmung > 50 – 75% der Stimmberechtigten\nDissens < 50% der Stimmberechtigten",
      "start_page": 28,
      "end_page": 29
    },
    {
      "heading": "Als Statements werden Darlegungen oder Erläuterungen von spezifischen",
      "text": "Sachverhalten oder Fragestellungen ohne unmittelbare\nHandlungsaufforderung bezeichnet. Sie werden entsprechend der\nVorgehensweise bei den Empfehlungen im Rahmen eines formalen\nKonsensusverfahrens verabschiedet und können entweder auf\nStudienergebnissen oder auf Expertenmeinungen beruhen.",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "Als ‘Good Clinical Practice (GCP)’ werden Empfehlungen bezeichnet, zu",
      "text": "denen keine Recherche nach Literatur durchgeführt wurde. In der Regel\nadressieren diese Empfehlungen Vorgehensweisen der guten klinischen\nPraxis, zu denen keine wissenschaftlichen Studien notwendig sind bzw.\nerwartet werden können. Für die Graduierung der GCPs wurden keine\nSymbole verwendet, die Stärke der Empfehlung ergibt sich aus der\nverwendeten Formulierung (soll/sollte/kann) entsprechend der Abstufung in\nTabelle 8.\nEmpfehlungen zum Staging und Klassifikation\nKonsensbasierte Empfehlung:\n• Die pTNM-Klassifikation soll als morphologisches Staging eingesetzt\nwerden. Um die Prognose eines HCCs beurteilen zu können, sollte das\nStaging-System zusätzlich das Tumorstadium, die Leberfunktion und den\nkörperlichen Leistungszustand des Patienten sowie den Effekt der\nTherapie auf die Lebenserwartung berücksichtigen. Die BCLC-\nKlassifikation sollte daher als integriertes Staging in der\nTherapiestratifikation des HCCs eingesetzt werden. [GCP; starker\nKonsens]\nBCLC-Klassifikation aus\nBCLC Allgemeinzustand Tumor Leberfunktion\nStadium\nA1 ECOG 0 1 Herd < 5 cm Keine portale\nHypertension\nA2\nA3\nA4\nB\nC\nD\nThera\napiee\nemp\nECO\nECO\nECO\nECO\nECO\nECO\npfehlung\nOG 0\nOG 0\nOG 0\nOG 0\nOG 1-2\nOG 3-4\ngen:\n1 Herd < 5 cm\n1 Herd < 5 cm\n1 Herd < 5 cm\ngroß multilokul\nGefäßinvasion\noder Metastase\negal\nnor\nBili\npor\nHy\nnor\nBili\npor\nHy\nBili\nCh\node\nlär Ch\node\nn Ch\nen ode\nCh\nrmales\nirubin\nrtale\nypertension\nrmales\nirubin\nrtale\nypertension\nirubin erhöh\nhild-Pugh A\ner B\nhild-Pugh A\ner B\nhild-Pugh A\ner B\nhild-Pugh C\nht\nTransarterielle Verfahren\nPatientenselektion für die Durchführung eines transarteriellen\nVerfahrens\nEvidenzbasierte Empfehlung:\n• Die transarterielle Chemoembolisation (TACE) soll bei Patienten\ndurchgeführt werden, bei denen ein kuratives Verfahren nicht möglich ist\nund die folgende Kriterien aufweisen: solitäres oder multifokales HCC\nohne extrahepatische Metastasierung und ECOG ≤ 2, im Stadium\nCHILD-Pugh A oder B. [LoE: 1b; GoR: A; starker Konsens]\nKonsensbasierte Empfehlung:\n• Die Indikation zur transarteriellen Chemoembolisation (TACE) soll in\neinem interdisziplinären Tumorboard gestellt werden. [GCP; starker\nKonsens]\n• Im Einzelfall kann die transarterielle Chemoembolisation (TACE) bei nicht\nführender systemischer Metastasierung erwogen werden. [GCP; starker\nKonsens]\n• Die transarterielle Chemoembolisation (TACE) kann bei Patienten mit\nsegmentaler Pfortaderthrombose erwogen werden. [GCP; starker\nKonsens]\nSystemische bzw. nicht auf die Leber beschränkte Verfahren\nPatientenselektion für eine systemische Therapie:\nEvidenzbasierte Empfehlung:\n• Bei HCC-Patienten im Stadium Child-Pugh A mit Fernmetastasen oder\neiner hepatischen Tumormanifestation, die lokoregionär nicht kontrolliert\nNCCN, 2017\nHepatobiliary\nCancers (Ve\ny\nersion\nwerden kann, mit einem ECOG-Status 0-2 und einer Lebenserwartung\nvon > 3 Monaten, soll eine Systemtherapie mit Sorafenib angeboten\nwerden. [LoE: 1a; GoR: A; starker Konsens] Leitlinienadaption [1]\n• Außer Sorafenib sollte eine Systemtherapie mit Einzelsubstanzen, eine\nKombinationschemotherapie, eine intraarterielle Chemotherapie oder\neine Kombination von Chemotherapie und Strahlentherapie nur im\nRahmen von klinischen Studien durchgeführt werden. [LoE: 2a; GoR: B;\nstarker Konsens] Leitlinienadaption [1]\nKonsensbasierte Empfehlung:\n• Die palliative Therapie mit Sorafenib sollte nicht über einen\nsymptomatischen und radiologischen Progress hinaus fortgesetzt\nwerden. Die Toxizität der Therapie soll engmaschig überwacht und\nberücksichtigt werden. [GCP; starker Konsens]\nEvidenzbasiertes Statement:\n• Bei HCC-Patienten im Stadium Child-Pugh B konnte für eine\nSorafenibtherapie bisher kein Überlebensvorteil nachgewiesen werden.\n[LoE: 3b; staker Konsens]\nEvidenzbasierte Empfehlung:\n• Bei HCC-Patienten im Stadium Child-Pugh B sollte keine Therapie mit\nSorafenib durchgeführt werden. [LoE: 3b; GoR: B; Konsens]\nKonsensbasierte Empfehlung:\nBei HCC-Patienten im Stadium Child-Pugh C soll keine Therapie mit\nSorafenib durchgeführt werden. [GCP; starker Konsens]\n]. Fragestellung/Zielsetzung:\nEmpfehlungen zur Diagnostik und Therapie von hepatobiliären\nKrebserkrankungen\nn\nGrundlage der Leitlinie\nLoE/G\nEmpfe\nGoR\nehlu\nunge\nen\nErg\nNICE, 2\nSorafen\nadvance\nhepatoc\ncarcinom\ngänzende\nnib for trea\ned\ncellular\nma",
      "start_page": 29,
      "end_page": 34
    },
    {
      "heading": " Siehe Anhang!",
      "text": "e Dokumente anderer Organisationen zu möglichen Komparatoren\nRecommendations\n1.1 Sorafenib is recommended as an option for treating advanced\nating hepatocellular carcinoma only for people with Child-Pugh grade A liver\nimpairment, only if the company provides sorafenib within the agreed\ncommercial access arrangement.\n1.2 This recommendation is not intended to affect treatment with sorafenib\nthatwas started in the NHS before this guidance was published. People\nhaving treatment outside this recommendation may continue without\nchange to the funding arrangements in place for them before this\nguidance was published, until they and their NHS clinician consider it\nappropriate to stop.\nEvidence:\n3.1 The appraisal committee (section 6) considered evidence submitted by\nBayer and a review of this submission by the evidence review group. This\nappraisal was a Cancer Drugs Fund reconsideration of the published NICE\ntechnology appraisal guidance on sorafenib for treating advanced\nhepatocellular carcinoma.\n3.2 The company's original submission presented clinical effectiveness data\nfrom the SHARP study. SHARP was a multicentre, double-blind, placebo-\ncontrolled, randomised trial in patients with advanced hepatocellular\ncarcinoma who had not received previous systemic treatment. The study\nincluded 602 patients and assessed the effect of sorafenib plus best\nsupportive care (n=299) compared with placebo plus best supportive care\n(n=303). The primary outcomes in\nSHARP were overall survival and time to symptomatic progression.\nNCCN\nN, 2017 [13]",
      "start_page": 34,
      "end_page": 35
    },
    {
      "heading": "Detaillierte Darstellung der Recherchestrategie",
      "text": "Cochrane Library (Cochrane Database of Systematic Reviews, Health Technology\nAssessment Database) am 02.10.2017",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "# Suchfrage",
      "text": "#1 MeSH descriptor: [Carcinoma, Hepatocellular] explode all trees\n#2 MeSH descriptor: [Liver Neoplasms] explode all trees\n#3 hepatoma*:ti,ab,kw or HCC:ti,ab,kw or hepatocarcinoma*:ti,ab,kw or hepatocellular next\ncarcinom*:ti,ab,kw or liver cell carcinoma*:ti,ab,kw\n#4 liver:ti or \"hepatic\":ti or \"hepatocellular\":ti or \"hepatobiliary\":ti\n#5 cancer*:ti or tumor* or tumour*:ti or neoplas*:ti or carcinoma* or adenocarcinoma*:ti or\nmalignan*:ti\n#6 #4 and #5\n#7 #1 or #2 or #3 or #6\n#8 #7 Publication Year from 2012 to 2017, in Cochrane Reviews (Reviews only) and\nTechnology Assessments",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "# Suchfrage",
      "text": "#1 Carcinoma, Hepatocellular[MeSH Terms]\n#2 Liver Neoplasms[mh:noexp]\n#3 ((hepatocarcinoma*[Title]) OR hepatoma*[Title]) OR HCC[Title]\n#4 (liver[Title] OR hepatic[Title] OR hepatocellular[Title] OR hepatobiliary[Title])\n#5 (((((((cancer*[Title]) OR tumor[Title]) OR tumors[Title]) OR tumour*[Title]) OR\nneoplasm*[Title]) OR carcinoma*[Title]) OR adenocarcinoma*[Title]) OR malignan*[Title]\n#6 #4 AND #5\n#7 #1 OR #2 OR #3 OR #6\n#8 ((((((((((((treatment*[Title/Abstract]) OR therapy[Title/Abstract]) OR\ntherapies[Title/Abstract]) OR therapeutic[Title/Abstract]) OR monotherap*[Title/Abstract])\nOR polytherap*[Title/Abstract]) OR pharmacotherap*[Title/Abstract]) OR\neffect*[Title/Abstract]) OR efficacy[Title/Abstract]) OR treating[Title/Abstract]) OR\ntreated[Title/Abstract]) OR management[Title/Abstract]) OR drug*[Title/Abstract]\n#9 #7 AND #8\n#10 carcinoma, hepatocellular/therapy[MeSH Terms]\n#11 liver neoplasms/therapy[mh:noexp]\n#12 #9 OR #10 OR #11\n#13 (#12) AND ((Meta-Analysis[ptyp] OR systematic[sb] OR Technical Report[ptyp]) OR\n(((((trials[Title/Abstract] OR studies[Title/Abstract] OR database*[Title/Abstract] OR\nliterature[Title/Abstract] OR publication*[Title/Abstract] OR Medline[Title/Abstract] OR\nEmbase[Title/Abstract] OR Cochrane[Title/Abstract] OR Pubmed[Title/Abstract])) AND\nsystematic*[Title/Abstract] AND (search*[Title/Abstract] OR research*[Title/Abstract]))) OR\n(((((((((((HTA[Title/Abstract]) OR technology assessment*[Title/Abstract]) OR technology\nreport*[Title/Abstract]) OR (systematic*[Title/Abstract] AND review*[Title/Abstract])) OR\n(systematic*[Title/Abstract] AND overview*[Title/Abstract])) OR meta\nanaly*[Title/Abstract]) OR (meta[Title/Abstract] AND analyz*[Title/Ab\n(meta[Title/Abstract] AND analys*[Title/Abstract])) OR (meta[Title/Ab\nanalyt*[Title/Abstract]))) OR (((review*[Title/Abstract]) OR overview*[\n((evidence[Title/Abstract]) AND based[Title/Abstract])))))\n#14 (#13) AND (\"2012/10/01\"[PDAT] : \"2017/10/02\"[PDAT])\n#15 (#14) NOT \"The Cochrane database of systematic reviews\"[Journal]",
      "start_page": 37,
      "end_page": 38
    },
    {
      "heading": "# Suchfrage",
      "text": "#1 Carcinoma, Hepatocellular[MeSH Terms]\n#2 Liver Neoplasms[mh:noexp]\n#3 ((hepatocarcinoma*[Title]) OR hepatoma*[Title]) OR HCC[Title]\n#4 (liver[Title] OR hepatic[Title] OR hepatocellular[Title] OR hepatobilia\n#5 (((((((cancer*[Title]) OR tumor[Title]) OR tumors[Title]) OR tumour*[\nneoplasm*[Title]) OR carcinoma*[Title]) OR adenocarcinoma*[Title]\n#6 #4 AND #5\n#7 #1 OR #2 OR #3 OR #6\n#8 #7 AND (Guideline[ptyp] OR Practice Guideline[ptyp] OR guideline*\nConsensus Development Conference[ptyp] OR Consensus Develop\nNIH[ptyp] OR recommendation*[Title]))\n#9 #8 (\"2012/10/01\"[PDAT] : \"2017/10/02\"[PDAT]))))\na-\nbstract])) O\nbstract] AN\n[Title/Abstr\nary[Title])\n[Title]) OR\n]) OR malig\n*[Title] OR\npment Con\nOR\nND\nract])\ngnan*\nR\nnferen\n) AND\n*[Title\nnce,\nD\ne]",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "Literatur:",
      "text": "1. Alberta Health Services (AHS). Hepatocellular carcinoma [online]. Edmonton\n(CAN): AHS; 2015. [Zugriff: 04.10.2017]. (Clinical Practice guideline; Band GI 007\nVersion 6). URL:\ncancer-guide-gi007-hepatocellular-carcinoma.pdf.\n2. Belinson S, Yang Y, Chopra R, Shankaran V, Samson D, Aronson N. Local\ntherapies for unresectable primary hepatocellular carcinoma [online]. Agency for\nHealthcare Research and Quality (AHRQ); 2013. [Zugriff: 04.10.2017]. URL:\nunresectable-executive-130524.pdf.\n3. Cao JH, Zhou J, Zhang XL, Ding X, Long QY. Meta-analysis on radiofrequency\nablation in combination with transarterial chemoembolization for the treatment of\nhepatocellular carcinoma. J Huazhong Univ Sci Technolog Med Sci 2014;34(5):692-\n4. Facciorusso A, Bellanti F, Villani R, Salvatore V, Muscatiello N, Piscaglia F, et\nal. Transarterial chemoembolization vs bland embolization in hepatocellular\ncarcinoma: A meta-analysis of randomized trials. United European Gastroenterol J\n5. Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen\nBundesausschusses über eine Änderung des Beschlusses über Maßnahmen zur\nQualitätssicherung bei Protonentherapie bei Patientinnen und Patienten mit\ninoperablem hepatozellulärem Karzinom (HCC): Verlängerung der Gültigkeitsdauer\nvom 27. November 2015 [online]. Berlin (GER): G-BA; 2015. [Zugriff: 12.10.2017].\nURL:\nMassnahmen_Protonen_hepato-Karzinom_Verlaengerung_BAnz.pdf?\n6. Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen\nBundesausschusses über Maßnahmen zur Qualitätssicherung bei Protonentherapie\nbei Patientinnen und Patienten mit inoperablem hepatozellulärem Karzinom in der\nFassung vom 16. Juli 2009; veröffentlicht im Bundesanzeiger 2009 (S.3326), in Kraft\ngetreten am 1. Januar 2010, zuletzt geändert am 27.November 2015, veröffentlicht\nim Bundesanzeiger AT 11.02.2016 B2 vom 11. Februar 2016, in Kraft getreten am\n12. Februar 2016 [online]. Berlin (GER): G-BA; 2015. [Zugriff: 12.10.2017]. URL:\ninop-HCC_2015-11-27_iK-2016-02-12.pdf.\n7. Huo YR, Eslick GD. Transcatheter Arterial Chemoembolization Plus Radiotherapy\nCompared With Chemoembolization Alone for Hepatocellular Carcinoma: A\nSystematic Review and Meta-analysis. JAMA Oncol 2015;1(6):756-765.\n8. Kong QF, Jiao JB, Chen QQ, Li L, Wang DG, Lv B. Comparative effectiveness of\nradiofrequency ablation with or without transarterial chemoembolization for\nhepatocellular carcinoma. Tumour Biol 2014;35(3):2655-2659.\n9. Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft und\nDeutschen Krebshilfe. Diagnostik und Therapie des hepatozellulären Karzinoms,\nLeitlinienreport 1.0 [online]. Registernummer 032 - 053OL. Berlin (GER):\nLeitlinienprogramm Onkologie; 2013. [Zugriff: 04.10.2017]. URL:\nLeitlinienreport-V1.0.pdf.\n10. Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft und\nDeutschen Krebshilfe,. Diagnostik und Therapie des hepatozellulären Karzinoms.\nLangversion 1.0 [online]. Registernummer 032-053OL. Berlin (GER):\nLeitlinienprogramm Onkologie; 2013. [Zugriff: 04.10.2017]. URL:\n053OLl_S3_Hepatozelluläres_Karzinom_Diagnostik_Therapie_2013-verlaengert.pdf.\n11. Li J, Liu W, Zhu W, Wu Y, Wu B. Transcatheter hepatic arterial chemoembolization\nand sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-\nblind controlled trials. Oncotarget 2017;8(35):59601-59608.",
      "start_page": 39,
      "end_page": 40
    },
    {
      "heading": "table under heading <Kriterien gemäß 5. Kapitel § 6 VerfO>",
      "text": "Row 1: I. Zweckmäßige Vergleichstherapie: Kriterien gemäß 5. Kapitel § 6 VerfO G-BA|\nRow 2: |\nRow 3: |\nRow 4: Lenvatinib|\nRow 5: [zur Behandlung des Leberzellkarzinoms]|\nRow 6: |\nRow 7: |\nRow 8: |\nRow 9: Kriterien gemäß 5. Kapitel § 6 VerfO|\nRow 10: |\nRow 11: Sofern als Vergleichstherapie eine Arzneimittelanwendung in Betracht kommt, muss das Arzneimittel grundsätzlich eine Zulassung für das Anwendungsgebiet haben.|Siehe Übersicht „II. Zugelassene Arzneimittel im Anwendungsgebiet“\nRow 12: Sofern als Vergleichstherapie eine nicht-medikamentöse Behandlung in Betracht kommt, muss diese im Rahmen der GKV erbringbar sein.|Eine nicht-medikamentöse Behandlung kommt als zweckmäßige Vergleichstherapie nicht in Betracht. Hierbei wird davon ausgegangen, dass sowohl eine kurative Behandlung (entsprechend BCLC-Stadium 0 und A) als auch eine lokoregionäre Therapie im BCLC-Stadium B, insbesondere eine transarterielle (Chemo)-Embolisation (TACE oder TAE), nicht (mehr) infrage kommt.\nRow 13: Beschlüsse/Bewertungen/Empfehlungen des Gemeinsamen Bundesausschusses zu im Anwendungsgebiet zugelassenen Arzneimitteln/nicht-medikamentösen Behandlungen|• Maßnahmen zur Qualitätssicherung bei Protonentherapie bei Patientinnen und Patienten mit inoperablem hepatozellulärem Karzinom; Beschluss vom 16. Juli 2009 und 27. November 2015 • Bewertung nach § 137h SGB V: Ultraschallgesteuerter hoch-intensiverfokussierter Ultraschall zur Behandlung des hepatozellulären Karzinoms ; Beschluss vom 16. März 2017\nRow 14: Die Vergleichstherapie soll nach dem allgemein anerkannten Stand der medizinischen Erkenntnisse zur zweckmäßigen Therapie im Anwendungsgebiet gehören.|Siehe systematische Literaturrecherche",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "table under heading <Handelsname>",
      "text": "Row 1: II. Zugelassene Arzneimittel im Anwendungsgebiet||\nRow 2: ||\nRow 3: ||\nRow 4: Wirkstoff||\nRow 5: ||Anwendungsgebiet\nRow 6: ATC-Code||\nRow 7: ||(Text aus Beratungsanforderung/Fachinformation)\nRow 8: Handelsname||\nRow 9: ||\nRow 10: ||\nRow 11: ||\nRow 12: Zu bewertendes Arzneimittel:||\nRow 13: ||\nRow 14: Lenvatinib||Vorläufig geplantes Anwendungsgebiet:\nRow 15: L01XE29||Lenvatinib ist angezeigt zur Behandlung des Leberzellkarzinoms\nRow 16: Lenvima®||\nRow 17: Mitomycin L01DC03 (generisch)||Mitomycin wird in der palliativen Tumortherapie eingesetzt. Bei intravenöser Gabe ist es in der Monochemotherapie oder in kombinierter zytostatischer Chemotherapie bei folgenden metastasierenden Tumoren wirksam: […] − fortgeschrittenes Leberzellkarzinom\nRow 18: Sorafenib L01XE05 Nexavar®||Leberzellkarzinom Nexavar ist angezeigt zur Behandlung des Leberzellkarzinoms (siehe Abschnitt 5.1).\nRow 19: Regorafenib1 L01 XE21 Stivarga®||Stivarga ist angezeigt als Monotherapie zur Behandlung von erwachsenen Patienten mit: […] - hepatozellulärem Karzinom (HCC), die zuvor mit Sorafenib behandelt wurden.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table under heading <Handelsname> (column 1)",
      "text": "Row 1: ||\nRow 2: ||\nRow 3: Wirkstoff||\nRow 4: ||Anwendungsgebiet\nRow 5: ATC-Code||\nRow 6: ||(Text aus Beratungsanforderung/Fachinfo\nRow 7: Handelsname||\nRow 8: ||\nRow 9: ||\nRow 10: ||\nRow 11: Zu bewertendes Arzneimittel:||\nRow 12: ||\nRow 13: Lenvatinib||Vorläufig geplantes Anwendungsgebiet:\nRow 14: L01XE29||Lenvatinib ist angezeigt zur Behandlung des Leberzellkarzinoms\nRow 15: Lenvima®||\nRow 16: Mitomycin L01DC03 (generisch)||\nRow 17: Sorafenib L01XE05 Nexavar®||\nRow 18: Regorafenib1 L01 XE21 Stivarga®||",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table under heading <Handelsname> (column 2)",
      "text": "Row 1: \nRow 2: \nRow 3: \nRow 4: ormation)\nRow 5: \nRow 6: \nRow 7: \nRow 8: \nRow 9: \nRow 10: \nRow 11: ",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table under heading <Handelsname> (column 3)",
      "text": "Row 1: \nRow 2: \nRow 3: \nRow 4: )\nRow 5: \nRow 6: \nRow 7: \nRow 8: \nRow 9: \nRow 10: \nRow 11: ",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table under heading <Handelsname> (column 4)",
      "text": "Row 1: \nRow 2: \nRow 3: \nRow 4: \nRow 5: \nRow 6: \nRow 7: \nRow 8: \nRow 9: \nRow 10: \nRow 11: ",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table under heading <Indikation:> (from previous page)",
      "text": "Row 1: Akdae|Arzneimittelkommission der deutschen Ärzteschaft\nRow 2: AWMF|Arbeitsgemeinschaft der wissenschaftlichen medizinischen Fachgesellschaften\nRow 3: ÄZQ|Ärztliches Zentrum für Qualität in der Medizin\nRow 4: CASP|Critical Appraisal Skills Programme\nRow 5: CCO|Cancer Care Ontario\nRow 6: DAHTA|Deutsche Agentur für Health Technology Assessment\nRow 7: DCR|disease control rate\nRow 8: DRKS|Deutsches Register Klinischer Studien\nRow 9: ESMO|European Society for Medical Oncology\nRow 10: G-BA|Gemeinsamer Bundesausschuss\nRow 11: GIN|Guidelines International Network\nRow 12: HCC|hepatozelluläres Karzinom\nRow 13: HFSR|hand and foot skin reactions\nRow 14: ICTRP|International Clinical Trials Registry Platform\nRow 15: IQWiG|Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen\nRow 16: ISRCTN|International Standard Randomised Controlled Trial Number\nRow 17: MPV|main portal vein\nRow 18: NCCN|National Comprehensive Cancer Network\nRow 19: NCI|National Cancer Institute\nRow 20: NGC|National Guideline Clearinghouse\nRow 21: NHS CRD|National Health Services Center for Reviews and Dissemination\nRow 22: NICE|National Institute for Health and Care Excellence\nRow 23: OS|Overall survival\nRow 24: PEI/PAI|percutaneous ethanol injection /percutaneous acetic acid injection\nRow 25: PVB|portal vein branches\nRow 26: RFA|radiofrequency ablation\nRow 27: SIGN|Scottish Intercollegiate Guidelines Network\nRow 28: TACE|Transarterial chemoembolization\nRow 29: TAE|Transarterial embolization\nRow 30: TRIP|Turn Research into Practice Database\nRow 31: TTP|Time to progression\nRow 32: TTSP|time to symptomatic progression\nRow 33: WHO|World Health Organization",
      "start_page": 6,
      "end_page": 6
    },
    {
      "heading": "table under heading <Indikation:> (from previous page)",
      "text": "Row 1: G-BA, 2015 [5]. Beschluss des Gemeinsamen Bundesausschusses über eine Änderung des Beschlusses über Maßnahmen zur Qualitätssicherung bei Protonentherapie bei Patientinnen und Patienten mit inoperablem hepatozellulärem Karzinom (HCC): Verlängerung der Gültigkeitsdauer Siehe auch: G-BA, 2015 [6].|Fazit: ,,Die Aussetzung des Bewertungsverfahrens zur Protonentherapie beim inoperablen HCC und der Beschluss über Maßnahmen zur Qualitätssicherung der Protonentherapie bei Patientinnen und Patienten mit inoperablem HCC werden bis zum 31. Dezember 2020 verlängert.’’",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table under heading <Cochrane Reviews>",
      "text": "Row 1: Roccarina D et al., 2017 [17]. Management of people with intermediate- stage hepatocellular carcinoma|1. Fragestellung To assess the comparative benefits and harms of different interventions used in the treatment of intermediate-stage hepatocellular carcinoma (BCLC stage B) through a network meta-analysis and to generate rankings of the available interventions according to their safety and efficacy.\nRow 2: |2. Methodik Population: Participants with intermediate-stage hepatocellular carcinoma (BCLC stage B) irrespective of the presence of cirrhosis, size and number of the tumours (provided they met the criteria of intermediate-stage hepatocellular carcinoma), presence or absence of portal hypertension, aetiology of hepatocellular carcinoma, and the future remnant liver volume. Randomised clinical trials in which participants had undergone liver transplantation previously were excluded. Intervention / Komparator: The following interventions that are possible treatments for intermediate-stage hepatocellular carcinoma either alone or in combination tested versus each other, or versus placebo or sham, or no intervention (supportive care) were condisered: • liver resection; • liver transplantation; • radiofrequency ablation; • microwave ablation; • other ablations (laser ablation, cryoablation, HIFU, irreversible electroporation); • alcohol injection; • acetic acid injection; • radiotherapy (stereotactic body radiotherapy or radioembolisation); • systemic chemotherapy; • TAE; • TACE; • supportive care. Endpunkte: Mortality, Adverse events, Quality of Life, Disease recurrence, Length of hospital stay and complications Suchzeitraum (Aktualität der Recherche): The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials Registry Platform, and randomised clinical trials registers to September 2016 were searched. Hinweis: We found only one comparison. Therefore, we did not perform the network meta-analysis Anzahl eingeschlossene Studien/Patienten (Gesamt): 3 trials with 430 participants. All three trials included supportive care (treatment to prevent, control, or relieve complications and side effects and improve comfort and quality of life) as a co-intervention. The trials assessed transarterial",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "table under heading <Systematische Reviews>",
      "text": "Row 1: |chemoembolisation (where anti-cancer drugs block the blood supply and treat the cancer through the vessels supplying the cancer), chemotherapy using sorafenib (a drug which blocks cancer growth), or a combination of transarterial chemoembolisation and sorafenib. Qualitätsbewertung der Studien: Cochrane risk of bias / GRADE\nRow 2: |3. Ergebnisdarstellung Qualität der Studien: The overall quality of evidence was low or very low and all the trials were at high risk of bias. • Over 18 to 30 months, 50% to 75% of participants died. There was no evidence of any difference between the people who received chemotherapy and those who did not receive chemotherapy. • None of the trials reported complications, health-related quality of life (a measure of a person’s satisfaction with their life and health), cancer recurrence, or length of hospital stay. • Overall, there is currently no evidence for benefit of any active treatment in addition to supportive treatment for intermediate-stage hepatocellular carcinoma. There is significant uncertainty on this and further high-quality randomised clinical trials are required.\nRow 3: |4. Fazit der Autoren: This review included only trial participants with intermediate stage hepatocellular carcinoma (i.e. BCLCB stage; i.e. large, multinodular, Child-Pugh status A to B, and performance status 0). Therefore, this review is applicable only to people with intermediate-stage hepatocellular carcinoma. It included a mixture of viral and non-viral aetiologies and people with cirrhotic and non-cirrhotic livers. Hence, the review is applicable to viral or non-viral aetiologies and people with cirrhotic and non-cirrhotic livers. None of the trials reported the proportion of people with portal hypertension. Therefore, it is not clear whether the findings of the review are applicable in people with portal hypertension. 5. Kommentar zum Review • Two trials were funded by the pharmaceutical industry; one trial did not report the source of funding.",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table under heading <Systematische Reviews>",
      "text": "Row 1: Silva JP et al., 2017 [19]. Transarterial chemoembolizatio n in hepatocellular|1. Fragestellung This systematic review sought to examine the role of TACE in the treatment of HCC with PVT in either the main portal vein (MPV) or portal vein branches (PVB).\nRow 2: |2. Methodik",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table under heading <3. Ergebnisdarstellung>",
      "text": "Row 1: carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis|Population: HCC patients with PVT. Intervention / Komparator: comparing TACE to another treatment for management of HCC with PVT Endpunkte: overall survival (OS), mRECIST response, and complication incidence Suchzeitraum (Aktualität der Recherche): PubMed was searched from January 1, 2006 to August 31, 2016. Anzahl eingeschlossene Studien/Patienten (Gesamt): 13 studies with 1933 TACE patients were included. Qualitätsbewertung der Studien: Newcastle–Ottawa Scale\nRow 2: |3. Ergebnisdarstellung Qualität der Studien: Several of the studies were non-randomized or retrospective, allowing for patient selection bias to influence the results (keine weiteren Angaben im Text) • Median OS (95% CI) was eight (5–15) months. Survival rates after one, three, and five years were 29% (20%–40%), 4% (1%–11%), and 1% (0%–5%), respectively. • Only 1% experienced liver failure and 18% had post-treatment complications. • Patients with MPV thrombosis had worse survival than PVB patients (p < 0.001), but similar mRECIST response rates (14% vs. 16%).\nRow 3: |4. Fazit der Autoren: TACE is a safe treatment for a highly selected population of HCC patients with PVT. Despite worse survival rates compared to PVB thrombosis, PVT in the MPV should not be considered an absolute contraindication to TACE. 5. Kommentar zum Review: • All studies were from Asian countries, with eight from China, one from Japan, three from Korea, and one from Taiwan. • heterogeneity between the studies\nRow 4: van Rosmalen BV et al., 2017 [20]. Systematic review of transarterial embolization for hepatocellular|1. Fragestellung This systematic review provides an overview of clinical outcomes after TAE, in bleeding and non-bleeding HCA.\nRow 5: |2. Methodik Population: patients with HCA Intervention/Komparator: TAE techniques",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "table under heading <patients (84%) not requiring surgery.>",
      "text": "Row 1: adenomas|Hinweis: Studies considering hepatic malignancies and tumours other than HCA, those reporting techniques other than TAE (such as radiofrequency ablation or hepatic artery ligation) and reviews were excluded. Endpunkte: tumour size, malignant transformation or adverse events. Suchzeitraum (Aktualität der Recherche): systematic literature search, up to 7 January 2016, of the PubMed and Embase databases was undertaken Anzahl eingeschlossene Studien/Patienten (Gesamt): 40 articles included a total of 851 patients (20 cohort studies and 20 case reports), of whom 151 (17,7 %) underwent TAE for 196 lesions. Qualitätsbewertung der Studien: To assess the quality of the selected studies, the Critical Appraisal Skills Programme (CASP) for cohort studies was used. Three items (what are the results of this study, how precise are the results and what are the implications of this study for practice?) of the CASP tool were left out of the critical appraisal. Regarding point 6 of the CASP tool, a follow-up of at least 12 months was considered appropriate to judge the effect on tumour size. The quality of case reports was not assessed because of likely selection bias. The Oxford Centre for Evidence-Based Medicine Levels of Evidence were determined for all studies, where level 1 is the highest level of evidence, and level 5 the lowest.\nRow 2: |3. Ergebnisdarstellung Qualität der Studien: Among the 20 studies, 18 were considered to provide level 2b evidence and two level 1b. Seven cohort studies scored ‘yes’ on all 11 items of the CASP tool. All case reports were considered as level 4 evidence. • Surgical treatment was avoided in 68 of 151 patients (45.0%). Elective TAE was performed in 49 patients involving 66 HCAs, with 41 of these patients (84%) not requiring surgery. • Major complications occurred in eight of 151 patients (5,3%); no death was reported. • Among cohort studies, complete tumour disappearance was observed in 10% of patients, and regression in 75%.\nRow 3: |4. Fazit der Autoren: Acute or elective TAE in the management of HCA seems safe. TAE in the elective setting offers a reasonable alternative to surgery, considering its minimally invasive and parenchyma-sparing properties, and the ability to reduce the size of tumours situated in a difficult anatomical position for surgery. Its influence on symptoms and whether it modifies risks of neoplastic regression remain unknown. 5. Kommentar zum Review: • Ausschließlich Kohortenstudien und Fallserien",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "table under heading <chemoembolization was found (risk ratio: 1.44, 1.08–1.92, p=0.01),>",
      "text": "Row 1: Facciorusso A et al., 2017 [4]. Transarterial chemoembolizatio n vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials|1. Fragestellung The objective of this article is to systematically analyze the results provided by randomized controlled trials comparing these two treatments in hepatocarcinoma patients.\nRow 2: |2. Methodik Population: hepatocarcinoma patients Intervention / Komparator: TACE vs. TAE Endpunkte: Survival rates assessed at one, two, and three years, objective response, one-year progression-free survival, and severe adverse event rate Suchzeitraum (Aktualität der Recherche): PubMed/Medline, Embase, Google Scholar, and Cochrane library databases were searched until February 2016. Anzahl eingeschlossene Studien/Patienten (Gesamt): 6 RCTs with 676 patients (342 treated with TACE and 334 with TAE) were included in the meta-analysis. Qualitätsbewertung der Studien: Cochrane Collaboration’s tool. Comparisons were performed by using the Mantel-Haenszel test in cases of low heterogeneity or DerSimonian and Laird test in cases of high heterogeneity.\nRow 3: |3. Ergebnisdarstellung Qualität der Studien: Three RCTs were considered high quality and three moderate quality. • No difference in one-year (risk ratio: 0.93, 0.85–1.03, p=0.16), two-year and three-year survival was observed. • Objective response and one-year progression-free survival showed no significant difference between the two treatments. • A statistically significant increase in severe toxicity after chemoembolization was found (risk ratio: 1.44, 1.08–1.92, p=0.01), although this result could be affected by the heterogeneity of techniques adopted.\nRow 4: |4. Fazit der Autoren: In conclusion, despite these weaknesses, our meta- analysis supports the non-superiority of TACE with respect to TAE, which in turn appears even safer particularly when compared to conventional chemoembolization. These conclusions need to be confirmed in broad non-inferiority trials with a large number of cases, strict selection of patients in terms of tumour burden, severity of liver dysfunction (as this strongly affects OS) as well as comorbidities (as these as well affect survival) and standardized modality of endovascular tumour treatment",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "table under heading <2014 [3]; Huo YR>",
      "text": "Row 1: |and reporting of adverse events.22 In the lack of a better source of evidence, the present meta-analysis appears to provide the most possible solid information on the comparison of TACE with TAE.\nRow 2: Wang X et al., 2016 [22]. Efficacy and Safety of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolizati on for Hepatocellular Carcinomas Compared with Radiofrequency Ablation Alone: A Time-to-Event Meta-Analysis Siehe auch: Wang Y et al., 2016 [23]; Kong QF et al., 2014 [8]; Ni JY et al., 2013 [15]; Liu Z et al., 2014 [12]; Cao JH et al., 2014 [3]; Huo YR|1. Fragestellung To compare the efficacy and safety of combined radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) with RFA alone for hepatocellular carcinomas (HCC).\nRow 3: |2. Methodik Population: Patients with HCC Intervention / Komparator: combination therapy of TACE and RFA versus RFA monotherapy Endpunkte: Overall survival, recurrence-free survival, major complications Suchzeitraum (Aktualität der Recherche): Pubmed, Embase, Cochrane Library, Chinese Biomedical Database (CBM), CNKI, and Google Scholar from their inception years to February 13, 2015 Anzahl eingeschlossene Studien/Patienten (Gesamt): 6 RCTs (16, 23-27) published between 2005 and 2013 with 534 patients were analyzed in this meta-analysis. Qualitätsbewertung der Studien: Risk of bias tool suggested by the Cochrane Handbook for Systematic Reviews of Interventions. In addition, to evaluate the quality of evidence from the pooled results, the Grading of Recommendations Assessment, Development, and Evaluation system (GRADE system) was employed.\nRow 4: |3. Ergebnisdarstellung Qualität der Studien:",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table under heading <et al., 2015 [7].>",
      "text": "Row 1: et al., 2015 [7].|• The meta-analysis showed that the combination of TACE and RFA is associated with a significantly longer overall survival (HR = 0.62, 95% CI: 0.49–0.78, p < 0.001) and recurrence-free survival (HR = 0.55, 95% CI: 0.40–0.76, p < 0.001) in contrast with RFA monotherapy. • The seemingly higher incidence of major complications in the combination group compared with RFA group did not reach statistical significance.\nRow 2: |4. Fazit der Autoren: In conclusion, this meta-analysis suggested that the combination of TACE and RFA is associated with significantly higher overall survival and recurrence-free survival than RFA monotherapy in the patients with HCC without significant difference in major complication between them. These results need to be validated in RCTs with better quality and larger sample sizes.\nRow 3: Li J et al., 2017 [11]. Transcatheter hepatic arterial chemoembolizatio n and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials. Siehe auch: Zeng J et al., 2016|1. Fragestellung A meta-analysis of transcatheter hepatic arterial chemoembolization (TACE) combined with sorafenib for hepatocellular carcinoma (HCC)\nRow 4: |2. Methodik Population: Patients with HCC. Patients were not suitable candidates for surgical resection; participants were 18 years of age or older. Intervention: TACE + sorafenib Komparator: Placebo Endpunkte: TTP or overall survival (OS); and reported adverse events Suchzeitraum (Aktualität der Recherche): MEDLINE, EMBASE, EBSCO, Springer, Ovid, and Cochrane Library databases search ending in 2016. Anzahl eingeschlossene Studien/Patienten (Gesamt): 4 placebo-controlled",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table under heading <et al., 2015 [7].> (column 2)",
      "text": "Row 1: • The meta-analysis showed that the combination of TACE and RFA is associated with a significantly longer overall survival (HR = 0.62, 95% CI: 0.49–0.78, p < 0.001) and recurrence-free survival (HR = 0.55, 95% CI: 0.40–0.76, p < 0.001) in contrast with RFA monotherapy. • The seemingly higher incidence of major complications in the combination group compared with RFA group did not reach statistical significance.\nRow 2: 4. Fazit der Autoren: In conclusion, this meta-analysis suggested that the combination of TACE and RFA is associated with significantly higher overall survival and recurrence-free survival than RFA monotherapy in the patients with HCC without significant difference in major complication between them. These results need to be validated in RCTs with better quality and larger sample sizes.\nRow 3: 1. Fragestellung A meta-analysis of transcatheter hepatic arterial chemoembolization (TACE) combined with sorafenib for hepatocellular carcinoma (HCC)\nRow 4: 2. Methodik Population: Patients with HCC. Patients were not suitable candidates for surgical resection; participants were 18 years of age or older. Intervention: TACE + sorafenib Komparator: Placebo Endpunkte: TTP or overall survival (OS); and reported adverse events Suchzeitraum (Aktualität der Recherche): MEDLINE, EMBASE, EBSCO, Springer, Ovid, and Cochrane Library databases search ending in 2016. Anzahl eingeschlossene Studien/Patienten (Gesamt): 4 placebo-controlled",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table under heading <3. Ergebnisdarstellung>",
      "text": "Row 1: [26].|RCTs were included in the meta-analysis with a total of 877 HCC cases from 14 countries, including China and the USA. Qualitätsbewertung der Studien: Quality assessment was performed based on the following criteria: Allocation was sufficiently randomized; blinding for allocation was sufficient; blinding for the intervention was sufficient; and loss to follow-up or exit status were evaluated.\nRow 2: |3. Ergebnisdarstellung Qualität der Studien: The various studies used different methods of randomization for allocation to the experimental and control groups. Blinding and randomization were determined to be adequate in all of the selected RCTs, whereas only one of these studies adequately described allocation concealment. The risks of selection, performance, or detection biases were not quantified in any of the included studies. • The TTP increased significantly in the experimental groups (hazard ration [HR]: 0.82; 95% CI: 0.69–0.97; p = 0.02), but OS did not improve significantly, compared with the control groups. • The risks of hand and foot skin reactions (HFSR), rash, fatigue, and diarrhea were significantly greater in the experimental groups (p < 0.05 for all), compared to those in the control groups, whereas the risk of nausea was statistically similar. Among these, the risk of HFSR was highest (risk ratio [RR]: 5.93; 95% CI: 2.00–17.53; p = 0.001), and a subgroup analysis of studies that lacked significant heterogeneity in the HFSR data showed a higher risk of HFSR (RR: 10.96; 95% CI: 5.54– 21.69; p < 0.05).\nRow 3: |4. Fazit der Autoren: In conclusion, although TACE plus sorafenib increases TTP in patients with HCC, it does not improve OS. Therefore, the increased risk of adverse events in patients receiving TACE plus sorafenib suggests that this combination therapy might not represent an improvement over treatment with TACE alone. The relatively small number of RCTs that met the selection criteria for our meta-analysis demonstrate the need for uniform application of clinical outcome indicators to facilitate future comparisons of studies of TACE plus sorafenib for the treatment of HCC. 5. Kommentar zum Review: • (…) We did not assess statistical power for our analysis, but the relatively small number of RCTs included in our meta-analysis represents a potential confounder of our findings. • (…) The small number of selected RCTs also precluded the use of funnel plots to assess whether publication bias influenced our findings, but the randomization and double blinding performed in all of the RCTs included in our meta-analysis likely minimized the potential effects of selection, performance, and detection biases.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "table under heading <3. Ergebnisdarstellung>",
      "text": "Row 1: Wang G et al., 2016 [21]. Sorafenib combined with transarterial chemoembolizatio n in patients with hepatocellular carcinoma: a meta-analysis and systematic review. Siehe auch: Zhang L et al., 2014 [27].|1. Fragestellung This study evaluated the efficacy and safety of TACE + sorafenib.\nRow 2: |2. Methodik Population: patients with advanced HCC Intervention/Komparator: TACE vs. TACE + Sorafenib Endpunkte: The primary outcome measure was time to progression (TTP), and the secondary outcomes measures were overall survival (OS) and adverse events. Suchzeitraum (Aktualität der Recherche): MEDLINE, the Cochrane Library, EMBASE, and the ISI Web of Knowledge were searched until 31 December 2013. Anzahl eingeschlossene Studien/Patienten (Gesamt): Five comparative studies (2 were randomized control trials) that included 899 patients Qualitätsbewertung der Studien: The Delphi list was used to assess the quality of the randomized controlled trials. The Newcastle-Ottawa scale was used to assess the quality of the nonrandomized controlled study.\nRow 3: |3. Ergebnisdarstellung Qualität der Studien: The quality of the data was evaluated for the two included studies that were randomized control trials using the Delphi list. The study of Kudo et al. received 8 points and of Sansonno et al. 7 points, indicating the data were of good quality. A risk for detection bias was present because the outcome assessors in both studies were not blinded. The Sansonno et al. study also did not include an intention-to-treat analysis. The quality of the Bai et al., Muhammad et al. and Qu et al. studies, which were non-randomized, was evaluated using the Newcastle-Ottawa scale. The Bai et al. data were considered of high quality as they received a score of 9. Muhammad et al. and Qu et al. received a score of 6 because they may have had selection bias as they did not explain the selection of participants. • Patients treated with TACE + sorafenib had better prognoses in terms of time to progression (TTP) compared to those with TACE + placebo or TACE alone; hazard ratios (HRs) ranged from 0.40 to 0.87, with the combined HR 0.61 (95 % CI 0.39–0.95, p = 0.031). • However, the combined HR for overall survival (OS) did not differ significantly between patients treated with TACE + sorafenib and those with TACE + placebo or TACE alone. • Sensitivity analysis indicated the findings for TTP may be overly influenced by at least one of the studies.\nRow 4: |4. Fazit der Autoren: In summary, our meta-analysis found that TACE + sorafenib can improve TTP. We did not find the combined therapy",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "table under heading <3. Ergebnisdarstellung> (column 2)",
      "text": "Row 1: 1. Fragestellung This study evaluated the efficacy and safety of TACE + sorafenib.\nRow 2: 2. Methodik Population: patients with advanced HCC Intervention/Komparator: TACE vs. TACE + Sorafenib Endpunkte: The primary outcome measure was time to progression (TTP), and the secondary outcomes measures were overall survival (OS) and adverse events. Suchzeitraum (Aktualität der Recherche): MEDLINE, the Cochrane Library, EMBASE, and the ISI Web of Knowledge were searched until 31 December 2013. Anzahl eingeschlossene Studien/Patienten (Gesamt): Five comparative studies (2 were randomized control trials) that included 899 patients Qualitätsbewertung der Studien: The Delphi list was used to assess the quality of the randomized controlled trials. The Newcastle-Ottawa scale was used to assess the quality of the nonrandomized controlled study.\nRow 3: 3. Ergebnisdarstellung Qualität der Studien: The quality of the data was evaluated for the two included studies that were randomized control trials using the Delphi list. The study of Kudo et al. received 8 points and of Sansonno et al. 7 points, indicating the data were of good quality. A risk for detection bias was present because the outcome assessors in both studies were not blinded. The Sansonno et al. study also did not include an intention-to-treat analysis. The quality of the Bai et al., Muhammad et al. and Qu et al. studies, which were non-randomized, was evaluated using the Newcastle-Ottawa scale. The Bai et al. data were considered of high quality as they received a score of 9. Muhammad et al. and Qu et al. received a score of 6 because they may have had selection bias as they did not explain the selection of participants. • Patients treated with TACE + sorafenib had better prognoses in terms of time to progression (TTP) compared to those with TACE + placebo or TACE alone; hazard ratios (HRs) ranged from 0.40 to 0.87, with the combined HR 0.61 (95 % CI 0.39–0.95, p = 0.031). • However, the combined HR for overall survival (OS) did not differ significantly between patients treated with TACE + sorafenib and those with TACE + placebo or TACE alone. • Sensitivity analysis indicated the findings for TTP may be overly influenced by at least one of the studies.\nRow 4: 4. Fazit der Autoren: In summary, our meta-analysis found that TACE + sorafenib can improve TTP. We did not find the combined therapy",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "table under heading <3. Ergebnisdarstellung>",
      "text": "Row 1: |improved OS. Additional randomized controlled studies are necessary to further investigate the clinical benefit of TACE + sorafenib in treating advanced HCC\nRow 2: Wang Z et al., 2013 [24]. Meta-analysis of the Efficacy of Sorafenib for Hepatocellular Carcinoma|1. Fragestellung By carrying out a meta-analysis of randomized controlled trials that compared sorafenib or combined chemotherapy with placebo or combined chemotherapy, the effectiveness of sorafenib in hepatocellular carcinoma was evaluated in the present study, which also provided clinical practice guidelines of evidence-based-medicine.\nRow 3: |2. Methodik Population: hepatocellular carcinoma patients Intervention: Sorafenib Komparator: Placebo Endpunkte: Overall survival (OS), time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR) and adverse reactions Suchzeitraum (Aktualität der Recherche): Review of PubMed citations concerning sorafenib treating hepatocellular carcinoma in randomized controlled trials from Jan 2000 to July 2012 Anzahl eingeschlossene Studien/Patienten (Gesamt): Finally, four papers documenting randomized controlled studies were included Qualitätsbewertung der Studien: RCT bias risk assessment methods in Cochrane handbook\nRow 4: |3. Ergebnisdarstellung Qualität der Studien: All trials included in this analysis were double-blind placebo-controlled randomized phase 3 clinical trials. Efficacy: Compared with controls, sorafenib was shown to significantly increase overall survival (OS), time to progression (TTP), and disease control rates (DCR), but not the time to symptom progression (TTSP) in hepatocellular carcinoma patients.",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "table under heading <3. Ergebnisdarstellung> (from previous page)",
      "text": "Row 1: |Adverse events: The incidence of grade-III/IV adverse reactions, including hand-foot-skin reactions, diarrhea, hypertension and skin rash or desquamation, in sorafenib treatment group was higher than that in controls. However, there was no significant difference in the incidence of hypodynamia between the two groups.\nRow 2: |4. Fazit der Autoren: Sorafenib exerts significant curative effects in hepatocellular carcinoma.\nRow 3: Belinson S et al., 2013 [2]. Local Therapies for Unresectable Primary Hepatocellular Carcinoma|1. Fragestellung To characterize the comparative effectiveness and harms of various local hepatic therapies for patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation. Local hepatic therapies include those related to ablation, embolization, and radiotherapy. KQ1. What is the comparative effectiveness of the various liver-directed therapies in patients with HCC who are not otherwise candidates for surgical resection or transplantation with no evidence of extrahepatic disease regarding survival and quality of life? KQ2. What are the comparative harms of the various liver-directed therapies in patients with HCC who are not otherwise candidates for surgical resection or transplantation with no evidence of extrahepatic disease regarding adverse events? KQ3. Are there differences in comparative effectiveness of various liver- directed therapies in patients with HCC who are not otherwise candidates for surgical resection or transplantation for specific patient and tumour characteristics, such as age, gender, disease etiology, and Child-Pugh score?\nRow 4: |2. Methodik Population: HCC in patients who meet all of the following criteria: • No extrahepatic spread • No portal invasion",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "table under heading <3. Ergebnisdarstellung> (from previous page)",
      "text": "Row 1: |• Child-Pugh class A or B disease • Eastern Cooperative Oncology Group (ECOG) status ≤1 and/or • BCLC stage A or B, or equivalent Intervention / Komparator: Local therapies (siehe Ergebnisteil) Endpunkte: overall survival and quality of life—and various adverse events Suchzeitraum (Aktualität der Recherche): MEDLINE and Embase from January 2000 to July 2012 Anzahl eingeschlossene Studien/Patienten (Gesamt): Siehe Ergebnisteil! Qualitätsbewertung der Studien: In the assessment of risk of bias in individual studies, we followed the Agency for Healthcare Research and Quality (AHRQ) “Methods Guide for Effectiveness and Comparative Effectiveness Reviews” (Methods Guide) / GRADE\nRow 2: |3. Ergebnisdarstellung Qualität der Studien: Siehe Ergebnisteil Overall Conclusions for Key Questions 1–3 • Six RCTs, four nonrandomized comparative studies, 35 case series, and three case reports comprised the body of literature. One RCT was rated as good, three were rated as fair and two were rated as poor quality. • The body of evidence for RFA compared with PEI/PAI was rated moderate strength to support better overall survival at 3 years for RFA compared with PEI/PAI with a low risk of bias. • The body of evidence for RFA compared with PEI/PAI was rated low strength to support increased TTP, improved local control, and a longer LOS for RFA compared with PEI/PAI, with a high risk of bias. • For all other comparisons, the body of evidence on overall survival, quality of life, disease progression, local control, LOS, days of missed work, and adverse events for local hepatic therapy for the treatment HCC is insufficient to support the effectiveness of one local hepatic therapy over another, due to the lack of comparative studies. • Studies with subgroup analyses were limited to the three studies reporting on the comparison of RFA to PEI/PAI. These analyses reviewed Child-Pugh class, lesion size, and multifocal disease for their effects on overall survival, but were not pre-specified. Lesion size was also examined by Lin et al 2004 for its effects on cancer-free survival and local recurrence. There is a low strength of evidence to support increased overall survival for RFA compared with PEI/PAI in patients with larger lesions with a high risk of bias. The evidence is insufficient to assess the effects lesion size on other outcomes of interest in this report and of other patient subgroups on any outcome of interest in this report. • The assessment of applicability of the study findings to clinical practice is limited by the poor characterization of the patient populations (e.g., number and size of metastases, performance status) and variations in the delivery of the interventions (e.g., surgical approach and dose and drugs delivered).",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "table under heading <3. Ergebnisdarstellung> (from previous page)",
      "text": "Row 1: |4. Fazit der Autoren: (…) For the comparison of RFA to PEI/PAI, our conclusions suggest that for these patients treatment with RFA confers a survival benefit at 3 years compared with PEI/PAI. In addition, TTP and local recurrence may be improved in patients treated with RFA compared with PEI/PAI. Patients treated with RFA also seem to have longer LOS after treatment compared with those treated with PEI/PAI. Beyond this evidence on the comparative effectiveness of these procedures was insufficient. Subsequent comparisons had only one or no comparative studies on a given treatment comparison. For these comparisons, evidence was insufficient for all outcomes; thus, there is no comparative evidence base to support decision making. In cases where comparative evidence existed, data were judged to be insufficient due to high risk of bias and/or imprecision of estimates.\nRow 2: Peng S et al., 2014 [16]. An Updated Meta- Analysis of Randomized Controlled Trials Assessing the Effect of Sorafenib in Advanced Hepatocellular Carcinoma.|1. Fragestellung The efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) remains controversial. Therefore, we conducted a meta- analysis to evaluate the efficacy and safety of sorafenib for treating patients with advanced HCC.\nRow 3: |2. Methodik Population: adult patients with advanced (unresectable or metastatic) HCC Intervention: sorafenib or sorafenib-based therapy Komparator: placebo or placebo-based (without sorafenib) therapy Endpunkte: primary: overall survival (OS); secondary: time to progression (TTP), overall response rate (ORR), and toxicity Suchzeitraum (Aktualität der Recherche): bis 03/2014 Anzahl eingeschlossene Studien/Patienten (Gesamt): 7 (n=3807) Qualitätsbewertung der Studien: The methodological quality of each study was assessed with the Jadad scale.\nRow 4: |3. Ergebnisdarstellung Qualität der Studien: In the present meta-analysis, all included studies were well-designed and of high quality (Jadad score range from 4 to 5). Overall survival (n=7 studies): • sorafenib was associated with a significant improvement in OS • (HR=0.74, 95% CI: 0.61, 0.90; P=0.002) • heterogeneity was significant (P=0.000, I2=77.0%) • Subgroup analysis: sorafenib was an effective treatment for patients with ECOG PS of 1–2 (HR=0.77, 95% CI: 0.60, 1.0; P=0.05), or macroscopic vascular invasion (MVI) and/or extrahepatic spread (EHS) (HR=0.65, 95% CI: 0.46, 0.93; P=0.02) • Begg and Egger tests provided no evidence of publication bias",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "table under heading <3. Ergebnisdarstellung> (from previous page, column 2)",
      "text": "Row 1: 4. Fazit der Autoren: (…) For the comparison of RFA to PEI/PAI, our conclusions suggest that for these patients treatment with RFA confers a survival benefit at 3 years compared with PEI/PAI. In addition, TTP and local recurrence may be improved in patients treated with RFA compared with PEI/PAI. Patients treated with RFA also seem to have longer LOS after treatment compared with those treated with PEI/PAI. Beyond this evidence on the comparative effectiveness of these procedures was insufficient. Subsequent comparisons had only one or no comparative studies on a given treatment comparison. For these comparisons, evidence was insufficient for all outcomes; thus, there is no comparative evidence base to support decision making. In cases where comparative evidence existed, data were judged to be insufficient due to high risk of bias and/or imprecision of estimates.\nRow 2: 1. Fragestellung The efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) remains controversial. Therefore, we conducted a meta- analysis to evaluate the efficacy and safety of sorafenib for treating patients with advanced HCC.\nRow 3: 2. Methodik Population: adult patients with advanced (unresectable or metastatic) HCC Intervention: sorafenib or sorafenib-based therapy Komparator: placebo or placebo-based (without sorafenib) therapy Endpunkte: primary: overall survival (OS); secondary: time to progression (TTP), overall response rate (ORR), and toxicity Suchzeitraum (Aktualität der Recherche): bis 03/2014 Anzahl eingeschlossene Studien/Patienten (Gesamt): 7 (n=3807) Qualitätsbewertung der Studien: The methodological quality of each study was assessed with the Jadad scale.\nRow 4: 3. Ergebnisdarstellung Qualität der Studien: In the present meta-analysis, all included studies were well-designed and of high quality (Jadad score range from 4 to 5). Overall survival (n=7 studies): • sorafenib was associated with a significant improvement in OS • (HR=0.74, 95% CI: 0.61, 0.90; P=0.002) • heterogeneity was significant (P=0.000, I2=77.0%) • Subgroup analysis: sorafenib was an effective treatment for patients with ECOG PS of 1–2 (HR=0.77, 95% CI: 0.60, 1.0; P=0.05), or macroscopic vascular invasion (MVI) and/or extrahepatic spread (EHS) (HR=0.65, 95% CI: 0.46, 0.93; P=0.02) • Begg and Egger tests provided no evidence of publication bias",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "table under heading <3. Ergebnisdarstellung> (from previous page)",
      "text": "Row 1: |Time to progression (n=6 studies): • TTP benefit existed in the sorafenib group when compared with the control group (HR=0.69, 95% CI: 0.55, 0.86; P=0.001) • heterogeneity was significant (P=0.000, I2=84.4%) • Subgroup analysis: significant TTP benefits of sorafenib treatment in the patients irrespective of MVI, EHS, and ECOG status • Begg and Egger tests provided no evidence of publication bias Overall response rate (n=5 studies): • sorafenib did not have a higher ORR when compared with other treatments (RR=0.85, 95% CI: 0.65, 1.11; P=0.10) • Begg and Egger tests provided no evidence of publication bias Adverse events (n=5 studies): • Sorafenib induced a significantly higher rate of hand-foot syndrome (RR=5.4, 95% CI: 1.8, 16.2; P=0.003), diarrhea (RR=1.45, 95% CI: 1.21, 2.34; P=0.003), fatigue (RR=1.70, 95% CI: 1.30, 2.23; P=0.000), and rash (RR=3.21, 95% CI: 1.65, 6.26; P=0.001)\nRow 2: |4. Fazit der Autoren: Treatment with sorafenib significantly improved OS and TTP in patients with advanced HCC. Additional large-scale, well-designed RCTs are needed to evaluate the efficacy of sorafenib-based therapy in the treatment of advanced HCC.\nRow 3: Xie ZB et al., 2014 [25]. Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review.|1. Fragestellung We investigated the efficacy and safety of TACE with or without chemotherapy in patients with advanced HCC.\nRow 4: |2. Methodik Population: patients with advanced HCC Intervention: arterial embolization with an antitumor drug (any type of embolization material or antitumor drug) Komparator: arterial embolization Endpunkte: primary: all-cause mortality (all-cause mortality defined as death due to any cause) or overall survival (OS); secondary: tumor response rate, adverse events, quality of life, liver function, and tumor reduction Suchzeitraum (Aktualität der Recherche): bis 04/2014 Anzahl eingeschlossene Studien/Patienten (Gesamt): 5 (n=582) Qualitätsbewertung der Studien: Two reviewers independently assessed the risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions.\nRow 5: |3. Ergebnisdarstellung Qualität der Studien: Risk of bias summary:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "table under heading <3. Ergebnisdarstellung> (from previous page, column 4)",
      "text": "Row 1: Time to progression (n=6 studies): • TTP benefit existed in the sorafenib group when compared with the control group (HR=0.69, 95% CI: 0.55, 0.86; P=0.001) • heterogeneity was significant (P=0.000, I2=84.4%) • Subgroup analysis: significant TTP benefits of sorafenib treatment in the patients irrespective of MVI, EHS, and ECOG status • Begg and Egger tests provided no evidence of publication bias Overall response rate (n=5 studies): • sorafenib did not have a higher ORR when compared with other treatments (RR=0.85, 95% CI: 0.65, 1.11; P=0.10) • Begg and Egger tests provided no evidence of publication bias Adverse events (n=5 studies): • Sorafenib induced a significantly higher rate of hand-foot syndrome (RR=5.4, 95% CI: 1.8, 16.2; P=0.003), diarrhea (RR=1.45, 95% CI: 1.21, 2.34; P=0.003), fatigue (RR=1.70, 95% CI: 1.30, 2.23; P=0.000), and rash (RR=3.21, 95% CI: 1.65, 6.26; P=0.001)\nRow 2: 4. Fazit der Autoren: Treatment with sorafenib significantly improved OS and TTP in patients with advanced HCC. Additional large-scale, well-designed RCTs are needed to evaluate the efficacy of sorafenib-based therapy in the treatment of advanced HCC.\nRow 3: 1. Fragestellung We investigated the efficacy and safety of TACE with or without chemotherapy in patients with advanced HCC.\nRow 4: 2. Methodik Population: patients with advanced HCC Intervention: arterial embolization with an antitumor drug (any type of embolization material or antitumor drug) Komparator: arterial embolization Endpunkte: primary: all-cause mortality (all-cause mortality defined as death due to any cause) or overall survival (OS); secondary: tumor response rate, adverse events, quality of life, liver function, and tumor reduction Suchzeitraum (Aktualität der Recherche): bis 04/2014 Anzahl eingeschlossene Studien/Patienten (Gesamt): 5 (n=582) Qualitätsbewertung der Studien: Two reviewers independently assessed the risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions.\nRow 5: 3. Ergebnisdarstellung Qualität der Studien: Risk of bias summary:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "table under heading <3. Ergebnisdarstellung> (from previous page)",
      "text": "Row 1: |All-cause mortality (n=5 studies): • no significant effect of all-cause mortality (RR=1.21, 95 % CI=0.74– 1.98, P=0.16) Survival (n=5 studies): • 1-year survival did not differ between TACE and TAE (RR=0.92, 95 % CI=0.83–1.01, P=0.53) Tumor response rates(n=1 study) • No significant difference were observed between TACE and TAE Adverse events (n=k. A.) • The most common adverse events were post-TACE syndromes (pain, fever, nausea, vomiting). • In the TACE group, the incidence of nausea and vomiting appeared to be increased compared with the TAE group • In contrast to TAE, TACE was found to cause myelosuppression due to the use of an antitumor drug. Quality of life (n=1 study) • None of the scores was significantly different between the two groups. Tumor reduction (n=k. A.) • The difference between TACE group and TAE group was not significant in this outcome. Liver function (n=1 study) • No significant differences of liver function between the two groups was observed (RR=1.17, 95 % CI=0.48–2.86, P=0.48).\nRow 2: |4. Fazit der Autoren: The efficacy of TACE is not superior to TAE in advanced HCC patients. Moreover, TACE was associated with an increased rate of adverse events than TAE. Improved strategies are needed to reduce the risk of post-TACE complications.\nRow 3: Shen A et al., 2013 [18]. A systematic Review of Sorafenib in Child-Pugh A Patients|1. Fragestellung We performed a systematic review of the efficacy and safety of sorafenib in Child-Pugh A patients with unresectable HCC. The value of sorafenib treatment in different subgroups was examined.\nRow 4: |2. Methodik",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "table under heading <3. Ergebnisdarstellung> (from previous page, column 2)",
      "text": "Row 1: All-cause mortality (n=5 studies): • no significant effect of all-cause mortality (RR=1.21, 95 % CI=0.74– 1.98, P=0.16) Survival (n=5 studies): • 1-year survival did not differ between TACE and TAE (RR=0.92, 95 % CI=0.83–1.01, P=0.53) Tumor response rates(n=1 study) • No significant difference were observed between TACE and TAE Adverse events (n=k. A.) • The most common adverse events were post-TACE syndromes (pain, fever, nausea, vomiting). • In the TACE group, the incidence of nausea and vomiting appeared to be increased compared with the TAE group • In contrast to TAE, TACE was found to cause myelosuppression due to the use of an antitumor drug. Quality of life (n=1 study) • None of the scores was significantly different between the two groups. Tumor reduction (n=k. A.) • The difference between TACE group and TAE group was not significant in this outcome. Liver function (n=1 study) • No significant differences of liver function between the two groups was observed (RR=1.17, 95 % CI=0.48–2.86, P=0.48).\nRow 2: 4. Fazit der Autoren: The efficacy of TACE is not superior to TAE in advanced HCC patients. Moreover, TACE was associated with an increased rate of adverse events than TAE. Improved strategies are needed to reduce the risk of post-TACE complications.\nRow 3: 1. Fragestellung We performed a systematic review of the efficacy and safety of sorafenib in Child-Pugh A patients with unresectable HCC. The value of sorafenib treatment in different subgroups was examined.\nRow 4: 2. Methodik",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "table under heading <group (sorafenib vs. placebo, RR, 1.85; 95% CI, 1.55, 2.20; P<0.001;>",
      "text": "Row 1: With Unresectable Hepatocellular Carcinoma.|Population: Child-Pugh A patients with unresectable HCC Intervention: sorafenib Komparator: placebo Endpunkte: disease control rate (DCR), time to progression (TTP), overall survival (OS), adverse events Definition DCR: DCR was defined as the percentage of patients who had a complete response, a partial response or stable disease (according to RECIST) that was maintained for at least 28 days after the first demonstration of that rating. Suchzeitraum (Aktualität der Recherche): bis 07/2012 Anzahl eingeschlossene Studien/Patienten (Gesamt): 5 (n=1462) Qualitätsbewertung der Studien: Two independent reviewers (A.S. and C.T.) evaluated the quality of each trial, according to the Cochrane Handbook for Systematic Reviews of Interventions.\nRow 2: |3. Ergebnisdarstellung Qualität der Studien: Two of the studies were found to have a low risk of bias and 3 trials had a high risk of bias. DCR (n=3 studies): • Sorafenib group had an 85% higher response rate than the placebo group (sorafenib vs. placebo, RR, 1.85; 95% CI, 1.55, 2.20; P<0.001; I2=0.0%) TTP (n=5 studies): • sorafenib improved the TTP significantly over placebo (HR, 0.61; 95% CI, 0.51, 0.73; P<0.001; I2=31.8%) Overall Survival (n=4 studies): • sorafenib treatment improved the survival of patients (HR, 0.71; 95% CI, 0.56, 0.89; P<0.001; I2=46.5%) Adverse events (n=5 studies): • sorafenib increased the incidence of overall AEs, such as fatigue (21.4%), alopecia (24.5%), hand-foot skin reaction (HFSR; 33.2%), rash or desquamation (23.0%), diarrhea (29.8%), nausea (11.8%), and hypertension (14.9%)\nRow 3: |4. Fazit der Autoren: Sorafenib was a moderately effective and safe oral drug for use in Child-Pugh A patients with unresectable HCC. Sorafenib monotherapy is not recommended for treating intermediate-stage HCC. More research is needed on the efficacy of sorafenib treatment in patients with prior local therapy.",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "table under heading <group (sorafenib vs. placebo, RR, 1.85; 95% CI, 1.55, 2.20; P<0.001;> (column 4)",
      "text": "Row 1: Population: Child-Pugh A patients with unresectable HCC Intervention: sorafenib Komparator: placebo Endpunkte: disease control rate (DCR), time to progression (TTP), overall survival (OS), adverse events Definition DCR: DCR was defined as the percentage of patients who had a complete response, a partial response or stable disease (according to RECIST) that was maintained for at least 28 days after the first demonstration of that rating. Suchzeitraum (Aktualität der Recherche): bis 07/2012 Anzahl eingeschlossene Studien/Patienten (Gesamt): 5 (n=1462) Qualitätsbewertung der Studien: Two independent reviewers (A.S. and C.T.) evaluated the quality of each trial, according to the Cochrane Handbook for Systematic Reviews of Interventions.\nRow 2: 3. Ergebnisdarstellung Qualität der Studien: Two of the studies were found to have a low risk of bias and 3 trials had a high risk of bias. DCR (n=3 studies): • Sorafenib group had an 85% higher response rate than the placebo group (sorafenib vs. placebo, RR, 1.85; 95% CI, 1.55, 2.20; P<0.001; I2=0.0%) TTP (n=5 studies): • sorafenib improved the TTP significantly over placebo (HR, 0.61; 95% CI, 0.51, 0.73; P<0.001; I2=31.8%) Overall Survival (n=4 studies): • sorafenib treatment improved the survival of patients (HR, 0.71; 95% CI, 0.56, 0.89; P<0.001; I2=46.5%) Adverse events (n=5 studies): • sorafenib increased the incidence of overall AEs, such as fatigue (21.4%), alopecia (24.5%), hand-foot skin reaction (HFSR; 33.2%), rash or desquamation (23.0%), diarrhea (29.8%), nausea (11.8%), and hypertension (14.9%)\nRow 3: 4. Fazit der Autoren: Sorafenib was a moderately effective and safe oral drug for use in Child-Pugh A patients with unresectable HCC. Sorafenib monotherapy is not recommended for treating intermediate-stage HCC. More research is needed on the efficacy of sorafenib treatment in patients with prior local therapy.",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "table under heading <Leitlinien>",
      "text": "Row 1: Alberta Health Services, 2015 [1]. HEPATOCELLULA R CARCINOMA|GUIDELINE QUESTIONS What are the goals of therapy and recommendations for the treatment of adult patients with: • intermediate stage hepatocellular carcinoma? • advanced stage hepatocellular carcinoma? • terminal stage hepatocellular carcinoma?\nRow 2: |Methodik Grundlage der Leitlinie This guideline was developed to promote evidence-based practice in Alberta. It was compiled from the results of randomized controlled trials and systematic reviews, derived from an English language and relevant term search of PubMed and MEDLINE from 1990 forward. It takes into consideration related information presented at local, national, and international meetings as well as the Alberta Provincial Gastrointestinal Tumour Team’s interpretation of the data. Suchzeitraum: This guideline was developed to promote evidence-based practice in Alberta. It was compiled from the results of randomized controlled trials and systematic reviews, derived from an English language and relevant term search of PubMed and MEDLINE from 1990 forward. It takes into consideration related information presented at local, national, and international meetings as well as the Alberta Provincial Gastrointestinal Tumour Team’s interpretation of the data. The 2015 update did not necessitate a full literature review; recommendations were modified based on a consensus discussion at the 2014 Annual Gastrointestinal Tumour Team Meeting. LoE/GoR Level Description of Evidence 1a Systematic reviews of randomized controlled trials 1b Individual randomized controlled trials 1c All or none randomized controlled trials 2a Systematic reviews of cohort studies 2b Individual cohort study or low quality randomized controlled trial 2c Outcomes research 3a Systematic review of case-control studies 3b Individual case-control study 4 Case series 5 Expert opinion without explicit critical appraisal or based on physiology, bench research, or “first principles”\nRow 3: |Freitext/Empfehlungen/Hinweise",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "table under heading <Leitlinien>",
      "text": "Row 1: Level|Description of Evidence\nRow 2: 1a|Systematic reviews of randomized controlled trials\nRow 3: 1b|Individual randomized controlled trials\nRow 4: 1c|All or none randomized controlled trials\nRow 5: 2a|Systematic reviews of cohort studies\nRow 6: 2b|Individual cohort study or low quality randomized controlled trial\nRow 7: 2c|Outcomes research\nRow 8: 3a|Systematic review of case-control studies\nRow 9: 3b|Individual case-control study\nRow 10: 4|Case series\nRow 11: 5|Expert opinion without explicit critical appraisal or based on physiology, bench research, or “first principles”",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "table under heading <Leitlinien> (column 4)",
      "text": "Row 1: GUIDELINE QUESTIONS What are the goals of therapy and recommendations for the treatment of adult patients with: • intermediate stage hepatocellular carcinoma? • advanced stage hepatocellular carcinoma? • terminal stage hepatocellular carcinoma?\nRow 2: Methodik Grundlage der Leitlinie This guideline was developed to promote evidence-based practice in Alberta. It was compiled from the results of randomized controlled trials and systematic reviews, derived from an English language and relevant term search of PubMed and MEDLINE from 1990 forward. It takes into consideration related information presented at local, national, and international meetings as well as the Alberta Provincial Gastrointestinal Tumour Team’s interpretation of the data. Suchzeitraum: This guideline was developed to promote evidence-based practice in Alberta. It was compiled from the results of randomized controlled trials and systematic reviews, derived from an English language and relevant term search of PubMed and MEDLINE from 1990 forward. It takes into consideration related information presented at local, national, and international meetings as well as the Alberta Provincial Gastrointestinal Tumour Team’s interpretation of the data. The 2015 update did not necessitate a full literature review; recommendations were modified based on a consensus discussion at the 2014 Annual Gastrointestinal Tumour Team Meeting. LoE/GoR Level Description of Evidence 1a Systematic reviews of randomized controlled trials 1b Individual randomized controlled trials 1c All or none randomized controlled trials 2a Systematic reviews of cohort studies 2b Individual cohort study or low quality randomized controlled trial 2c Outcomes research 3a Systematic review of case-control studies 3b Individual case-control study 4 Case series 5 Expert opinion without explicit critical appraisal or based on physiology, bench research, or “first principles”\nRow 3: Freitext/Empfehlungen/Hinweise",
      "start_page": 24,
      "end_page": 24
    },
    {
      "heading": "table under heading <Leitlinien> (from previous page)",
      "text": "Row 1: |\nRow 2: DKG, 2013 [9,10]. Diagnostik und|Fragestellung/Zielsetzung: Empfehlungen zur Diagnostik und Therapie des hepatozellulären Karzinoms\nRow 3: |Methodik",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "table under heading <Schema der Evidenzgraduierung nach Oxford>",
      "text": "Row 1: Therapie des hepatozellulären Karzinoms|Grundlage der Leitlinie Grundlage der Leitlinie: Die Entwicklung der Leitlinie erfolgte in einem strukturierten Prozess nach dem AWMF-Regelwerk (http://www.awmf.org/leitlinien/awmf-regelwerk.html). Als Ausgangspunkt für eine Literaturrecherche erfolgte im Vorfeld eine Gliederung der Leitlinie nach verschiedenen Themenkomplexen. Die Schlüsselfragen wurden im interdisziplinären Konsensus auf dem ersten Arbeitstreffen (Kick-off-Meeting) identifiziert. Um die Schlüsselfragen beantworten zu können, wurde ein Konzept zu ihrer gegenüberstellenden Darstellung mit den Aussagen internationaler Leitlinien und der ihnen zugrundeliegenden Literatur entwickelt. In einem zweiten Treffen unter Beteiligung aller Mandatsträger der unterschiedlichen Fachgesellschaften und Institutionen wurde geklärt, auf welcher Grundlage (De-Novo-Recherche, Leitlinienadaptation oder reiner Expertenkonsens) die Schlüsselfragen beantwortet werden sollen Suchzeitraum: Im Oktober 2009 und Januar 2010 erfolgte die zentrale und systematische Suche nach Leitlinien für die Diagnostik und Therapie des hepatozellulären Karzinoms, die entweder auf Englisch oder Deutsch zwischen Januar 2000 bis November 2009 publiziert wurden. • Gültigkeit nach Überprüfung durch das LL-Sekretariat verlängert bis 30.04.2018 Schema der Evidenzgraduierung nach Oxford Zur Klassifikation des Verzerrungsrisikos der identifizierten Studien wurde in dieser Leitlinie das in Tabelle 7 aufgeführte System des Oxford Centre for Evidence-based Medicine in der Version von 2009 verwendet. Dieses System sieht die Klassifikation der Studien für verschiedene klinische Fragestellungen (Nutzen von Therapie, prognostische Aussagekraft, diagnostische Wertigkeit) vor. LoE/GoR Schema der Evidenzgraduierung nach Oxford",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "table under heading <Schema der Evidenzgraduierung nach Oxford> (from previous page)",
      "text": "Row 1: |",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "table under heading <Schema der Empfehlungsgraduierung>",
      "text": "Row 1: |Schema der Empfehlungsgraduierung Die OL-Methodik sieht eine Vergabe von Empfehlungsgraden durch die Leitlinien-Autoren im Rahmen eines formalen Konsensusverfahrens vor. Dementsprechend wurde ein durch die AWMF moderierter, mehrteiliger nominaler Gruppenprozess durchgeführt. Am Ende dieses Gruppenprozesses wurden die Empfehlungen von den stimmberechtigten Mandatsträgern (siehe Kapitel 1.7) formal abgestimmt. Die Ergebnisse der jeweiligen Abstimmungen sind entsprechend den Kategorien in Tabelle 9 den Empfehlungen zugeordnet. In der Leitlinie werden zu allen evidenzbasierten Statements (siehe Kapitel 2.2.3) und Empfehlungen das Evidenzlevel (siehe 2.2.1) der zugrundeliegenden Studien sowie bei Empfehlungen zusätzlich die Stärke der Empfehlung (Empfehlungsgrad) ausgewiesen. Hinsichtlich der Stärke der Empfehlung werden in dieser Leitlinie drei Empfehlungsgrade unterschieden (siehe Tabelle 8), die sich auch in der Formulierung der Empfehlungen jeweils widerspiegeln.",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "table under heading <Als ‘Good Clinical Practice (GCP)’ werden Empfehlungen bezeichnet, zu>",
      "text": "Row 1: |Tabelle 8: Schema der Empfehlungsgraduierung Empfehlungsgrad Beschreibung Syntax A Starke Empfehlung soll B Empfehlung sollte C Empfehlung offen kann Tabelle 9: Konsensusstärke Konsenstärke Prozentuale Zustimmung Starker Konsens > 95% der Stimmberechtigten Konsens > 75 – 95% der Stimmberechtigten Mehrheitliche Zustimmung > 50 – 75% der Stimmberechtigten Dissens < 50% der Stimmberechtigten Statements Als Statements werden Darlegungen oder Erläuterungen von spezifischen Sachverhalten oder Fragestellungen ohne unmittelbare Handlungsaufforderung bezeichnet. Sie werden entsprechend der Vorgehensweise bei den Empfehlungen im Rahmen eines formalen Konsensusverfahrens verabschiedet und können entweder auf Studienergebnissen oder auf Expertenmeinungen beruhen. Good Clinical Practice (GCP) Als ‘Good Clinical Practice (GCP)’ werden Empfehlungen bezeichnet, zu denen keine Recherche nach Literatur durchgeführt wurde. In der Regel adressieren diese Empfehlungen Vorgehensweisen der guten klinischen Praxis, zu denen keine wissenschaftlichen Studien notwendig sind bzw. erwartet werden können. Für die Graduierung der GCPs wurden keine Symbole verwendet, die Stärke der Empfehlung ergibt sich aus der verwendeten Formulierung (soll/sollte/kann) entsprechend der Abstufung in Tabelle 8.\nRow 2: |Empfehlungen zum Staging und Klassifikation Konsensbasierte Empfehlung: • Die pTNM-Klassifikation soll als morphologisches Staging eingesetzt werden. Um die Prognose eines HCCs beurteilen zu können, sollte das Staging-System zusätzlich das Tumorstadium, die Leberfunktion und den körperlichen Leistungszustand des Patienten sowie den Effekt der Therapie auf die Lebenserwartung berücksichtigen. Die BCLC- Klassifikation sollte daher als integriertes Staging in der Therapiestratifikation des HCCs eingesetzt werden. [GCP; starker Konsens] BCLC-Klassifikation aus BCLC Allgemeinzustand Tumor Leberfunktion Stadium A1 ECOG 0 1 Herd < 5 cm Keine portale Hypertension",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "table under heading <Als ‘Good Clinical Practice (GCP)’ werden Empfehlungen bezeichnet, zu>",
      "text": "Row 1: Empfehlungsgrad|Beschreibung|Syntax\nRow 2: A|Starke Empfehlung|soll\nRow 3: B|Empfehlung|sollte\nRow 4: C|Empfehlung offen|kann",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "table under heading <Als ‘Good Clinical Practice (GCP)’ werden Empfehlungen bezeichnet, zu>",
      "text": "Row 1: Konsenstärke|Prozentuale Zustimmung\nRow 2: Starker Konsens|> 95% der Stimmberechtigten\nRow 3: Konsens|> 75 – 95% der Stimmberechtigten\nRow 4: Mehrheitliche Zustimmung|> 50 – 75% der Stimmberechtigten\nRow 5: Dissens|< 50% der Stimmberechtigten",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "table under heading <Als ‘Good Clinical Practice (GCP)’ werden Empfehlungen bezeichnet, zu>",
      "text": "Row 1: BCLC Stadium|Allgemeinzustand|Tumor|Leberfunktion\nRow 2: A1|ECOG 0|1 Herd < 5 cm|Keine portale Hypertension",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "table under heading <Als ‘Good Clinical Practice (GCP)’ werden Empfehlungen bezeichnet, zu> (from previous page)",
      "text": "Row 1: |normales Bilirubin A2 ECOG 0 1 Herd < 5 cm portale Hypertension normales Bilirubin A3 ECOG 0 1 Herd < 5 cm portale Hypertension Bilirubin erhöht A4 ECOG 0 1 Herd < 5 cm Child-Pugh A oder B B ECOG 0 groß multilokulär Child-Pugh A oder B C ECOG 1-2 Gefäßinvasion Child-Pugh A oder Metastasen oder B D ECOG 3-4 egal Child-Pugh C Therapieempfehlungen:",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "table under heading <Als ‘Good Clinical Practice (GCP)’ werden Empfehlungen bezeichnet, zu> (from previous page)",
      "text": "Row 1: |||normales Bilirubin\nRow 2: A2|ECOG 0|1 Herd < 5 cm|portale Hypertension normales Bilirubin\nRow 3: A3|ECOG 0|1 Herd < 5 cm|portale Hypertension Bilirubin erhöht\nRow 4: A4|ECOG 0|1 Herd < 5 cm|Child-Pugh A oder B\nRow 5: B|ECOG 0|groß multilokulär|Child-Pugh A oder B\nRow 6: C|ECOG 1-2|Gefäßinvasion oder Metastasen|Child-Pugh A oder B\nRow 7: D|ECOG 3-4|egal|Child-Pugh C",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "table under heading <Als ‘Good Clinical Practice (GCP)’ werden Empfehlungen bezeichnet, zu> (from previous page)",
      "text": "Row 1: |Transarterielle Verfahren Patientenselektion für die Durchführung eines transarteriellen Verfahrens Evidenzbasierte Empfehlung: • Die transarterielle Chemoembolisation (TACE) soll bei Patienten durchgeführt werden, bei denen ein kuratives Verfahren nicht möglich ist und die folgende Kriterien aufweisen: solitäres oder multifokales HCC ohne extrahepatische Metastasierung und ECOG ≤ 2, im Stadium CHILD-Pugh A oder B. [LoE: 1b; GoR: A; starker Konsens] Konsensbasierte Empfehlung: • Die Indikation zur transarteriellen Chemoembolisation (TACE) soll in einem interdisziplinären Tumorboard gestellt werden. [GCP; starker Konsens] • Im Einzelfall kann die transarterielle Chemoembolisation (TACE) bei nicht führender systemischer Metastasierung erwogen werden. [GCP; starker Konsens] • Die transarterielle Chemoembolisation (TACE) kann bei Patienten mit segmentaler Pfortaderthrombose erwogen werden. [GCP; starker Konsens] Systemische bzw. nicht auf die Leber beschränkte Verfahren Patientenselektion für eine systemische Therapie: Evidenzbasierte Empfehlung: • Bei HCC-Patienten im Stadium Child-Pugh A mit Fernmetastasen oder einer hepatischen Tumormanifestation, die lokoregionär nicht kontrolliert",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "table under heading <Als ‘Good Clinical Practice (GCP)’ werden Empfehlungen bezeichnet, zu> (from previous page)",
      "text": "Row 1: |werden kann, mit einem ECOG-Status 0-2 und einer Lebenserwartung von > 3 Monaten, soll eine Systemtherapie mit Sorafenib angeboten werden. [LoE: 1a; GoR: A; starker Konsens] Leitlinienadaption [1] • Außer Sorafenib sollte eine Systemtherapie mit Einzelsubstanzen, eine Kombinationschemotherapie, eine intraarterielle Chemotherapie oder eine Kombination von Chemotherapie und Strahlentherapie nur im Rahmen von klinischen Studien durchgeführt werden. [LoE: 2a; GoR: B; starker Konsens] Leitlinienadaption [1] Konsensbasierte Empfehlung: • Die palliative Therapie mit Sorafenib sollte nicht über einen symptomatischen und radiologischen Progress hinaus fortgesetzt werden. Die Toxizität der Therapie soll engmaschig überwacht und berücksichtigt werden. [GCP; starker Konsens] Evidenzbasiertes Statement: • Bei HCC-Patienten im Stadium Child-Pugh B konnte für eine Sorafenibtherapie bisher kein Überlebensvorteil nachgewiesen werden. [LoE: 3b; staker Konsens] Evidenzbasierte Empfehlung: • Bei HCC-Patienten im Stadium Child-Pugh B sollte keine Therapie mit Sorafenib durchgeführt werden. [LoE: 3b; GoR: B; Konsens] Konsensbasierte Empfehlung: Bei HCC-Patienten im Stadium Child-Pugh C soll keine Therapie mit Sorafenib durchgeführt werden. [GCP; starker Konsens]\nRow 2: NCCN, 2017 [13]. Hepatobiliary Cancers (Version 3.2017)|Fragestellung/Zielsetzung: Empfehlungen zur Diagnostik und Therapie von hepatobiliären Krebserkrankungen\nRow 3: |Methodik Grundlage der Leitlinie",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "table under heading <Als ‘Good Clinical Practice (GCP)’ werden Empfehlungen bezeichnet, zu> (from previous page, column 3)",
      "text": "Row 1: werden kann, mit einem ECOG-Status 0-2 und einer Lebenserwartung von > 3 Monaten, soll eine Systemtherapie mit Sorafenib angeboten werden. [LoE: 1a; GoR: A; starker Konsens] Leitlinienadaption [1] • Außer Sorafenib sollte eine Systemtherapie mit Einzelsubstanzen, eine Kombinationschemotherapie, eine intraarterielle Chemotherapie oder eine Kombination von Chemotherapie und Strahlentherapie nur im Rahmen von klinischen Studien durchgeführt werden. [LoE: 2a; GoR: B; starker Konsens] Leitlinienadaption [1] Konsensbasierte Empfehlung: • Die palliative Therapie mit Sorafenib sollte nicht über einen symptomatischen und radiologischen Progress hinaus fortgesetzt werden. Die Toxizität der Therapie soll engmaschig überwacht und berücksichtigt werden. [GCP; starker Konsens] Evidenzbasiertes Statement: • Bei HCC-Patienten im Stadium Child-Pugh B konnte für eine Sorafenibtherapie bisher kein Überlebensvorteil nachgewiesen werden. [LoE: 3b; staker Konsens] Evidenzbasierte Empfehlung: • Bei HCC-Patienten im Stadium Child-Pugh B sollte keine Therapie mit Sorafenib durchgeführt werden. [LoE: 3b; GoR: B; Konsens] Konsensbasierte Empfehlung: Bei HCC-Patienten im Stadium Child-Pugh C soll keine Therapie mit Sorafenib durchgeführt werden. [GCP; starker Konsens]\nRow 2: Fragestellung/Zielsetzung: Empfehlungen zur Diagnostik und Therapie von hepatobiliären Krebserkrankungen\nRow 3: Methodik Grundlage der Leitlinie",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "table under heading <Als ‘Good Clinical Practice (GCP)’ werden Empfehlungen bezeichnet, zu> (from previous page)",
      "text": "Row 1: |LoE/GoR\nRow 2: |Empfehlungen",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "table under heading < Siehe Anhang!>",
      "text": "Row 1: | Siehe Anhang!",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "table under heading < Siehe Anhang!>",
      "text": "Row 1: NICE, 2017 [14]. Sorafenib for treating advanced hepatocellular carcinoma|Recommendations 1.1 Sorafenib is recommended as an option for treating advanced hepatocellular carcinoma only for people with Child-Pugh grade A liver impairment, only if the company provides sorafenib within the agreed commercial access arrangement. 1.2 This recommendation is not intended to affect treatment with sorafenib thatwas started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Evidence: 3.1 The appraisal committee (section 6) considered evidence submitted by Bayer and a review of this submission by the evidence review group. This appraisal was a Cancer Drugs Fund reconsideration of the published NICE technology appraisal guidance on sorafenib for treating advanced hepatocellular carcinoma. 3.2 The company's original submission presented clinical effectiveness data from the SHARP study. SHARP was a multicentre, double-blind, placebo- controlled, randomised trial in patients with advanced hepatocellular carcinoma who had not received previous systemic treatment. The study included 602 patients and assessed the effect of sorafenib plus best supportive care (n=299) compared with placebo plus best supportive care (n=303). The primary outcomes in SHARP were overall survival and time to symptomatic progression.",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "table under heading <# Suchfrage>",
      "text": "Row 1: #|Suchfrage\nRow 2: #1|MeSH descriptor: [Carcinoma, Hepatocellular] explode all trees\nRow 3: #2|MeSH descriptor: [Liver Neoplasms] explode all trees\nRow 4: #3|hepatoma*:ti,ab,kw or HCC:ti,ab,kw or hepatocarcinoma*:ti,ab,kw or hepatocellular next carcinom*:ti,ab,kw or liver cell carcinoma*:ti,ab,kw\nRow 5: #4|liver:ti or \"hepatic\":ti or \"hepatocellular\":ti or \"hepatobiliary\":ti\nRow 6: #5|cancer*:ti or tumor* or tumour*:ti or neoplas*:ti or carcinoma* or adenocarcinoma*:ti or malignan*:ti\nRow 7: #6|#4 and #5\nRow 8: #7|#1 or #2 or #3 or #6\nRow 9: #8|#7 Publication Year from 2012 to 2017, in Cochrane Reviews (Reviews only) and Technology Assessments",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "table under heading <# Suchfrage>",
      "text": "Row 1: #|Suchfrage\nRow 2: #1|Carcinoma, Hepatocellular[MeSH Terms]\nRow 3: #2|Liver Neoplasms[mh:noexp]\nRow 4: #3|((hepatocarcinoma*[Title]) OR hepatoma*[Title]) OR HCC[Title]\nRow 5: #4|(liver[Title] OR hepatic[Title] OR hepatocellular[Title] OR hepatobiliary[Title])\nRow 6: #5|(((((((cancer*[Title]) OR tumor[Title]) OR tumors[Title]) OR tumour*[Title]) OR neoplasm*[Title]) OR carcinoma*[Title]) OR adenocarcinoma*[Title]) OR malignan*[Title]\nRow 7: #6|#4 AND #5\nRow 8: #7|#1 OR #2 OR #3 OR #6\nRow 9: #8|((((((((((((treatment*[Title/Abstract]) OR therapy[Title/Abstract]) OR therapies[Title/Abstract]) OR therapeutic[Title/Abstract]) OR monotherap*[Title/Abstract]) OR polytherap*[Title/Abstract]) OR pharmacotherap*[Title/Abstract]) OR effect*[Title/Abstract]) OR efficacy[Title/Abstract]) OR treating[Title/Abstract]) OR treated[Title/Abstract]) OR management[Title/Abstract]) OR drug*[Title/Abstract]\nRow 10: #9|#7 AND #8\nRow 11: #10|carcinoma, hepatocellular/therapy[MeSH Terms]\nRow 12: #11|liver neoplasms/therapy[mh:noexp]\nRow 13: #12|#9 OR #10 OR #11\nRow 14: #13|(#12) AND ((Meta-Analysis[ptyp] OR systematic[sb] OR Technical Report[ptyp]) OR (((((trials[Title/Abstract] OR studies[Title/Abstract] OR database*[Title/Abstract] OR literature[Title/Abstract] OR publication*[Title/Abstract] OR Medline[Title/Abstract] OR Embase[Title/Abstract] OR Cochrane[Title/Abstract] OR Pubmed[Title/Abstract])) AND systematic*[Title/Abstract] AND (search*[Title/Abstract] OR research*[Title/Abstract]))) OR (((((((((((HTA[Title/Abstract]) OR technology assessment*[Title/Abstract]) OR technology report*[Title/Abstract]) OR (systematic*[Title/Abstract] AND review*[Title/Abstract])) OR",
      "start_page": 37,
      "end_page": 37
    },
    {
      "heading": "table under heading <# Suchfrage>",
      "text": "Row 1: |(systematic*[Title/Abstract] AND overview*[Title/Abstract])) OR meta- analy*[Title/Abstract]) OR (meta[Title/Abstract] AND analyz*[Title/Abstract])) OR (meta[Title/Abstract] AND analys*[Title/Abstract])) OR (meta[Title/Abstract] AND analyt*[Title/Abstract]))) OR (((review*[Title/Abstract]) OR overview*[Title/Abstract]) AND ((evidence[Title/Abstract]) AND based[Title/Abstract])))))\nRow 2: #14|(#13) AND (\"2012/10/01\"[PDAT] : \"2017/10/02\"[PDAT])\nRow 3: #15|(#14) NOT \"The Cochrane database of systematic reviews\"[Journal]",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "table under heading <# Suchfrage>",
      "text": "Row 1: #|Suchfrage\nRow 2: #1|Carcinoma, Hepatocellular[MeSH Terms]\nRow 3: #2|Liver Neoplasms[mh:noexp]\nRow 4: #3|((hepatocarcinoma*[Title]) OR hepatoma*[Title]) OR HCC[Title]\nRow 5: #4|(liver[Title] OR hepatic[Title] OR hepatocellular[Title] OR hepatobiliary[Title])\nRow 6: #5|(((((((cancer*[Title]) OR tumor[Title]) OR tumors[Title]) OR tumour*[Title]) OR neoplasm*[Title]) OR carcinoma*[Title]) OR adenocarcinoma*[Title]) OR malignan*[Title]\nRow 7: #6|#4 AND #5\nRow 8: #7|#1 OR #2 OR #3 OR #6\nRow 9: #8|#7 AND (Guideline[ptyp] OR Practice Guideline[ptyp] OR guideline*[Title] OR Consensus Development Conference[ptyp] OR Consensus Development Conference, NIH[ptyp] OR recommendation*[Title]))\nRow 10: #9|#8 (\"2012/10/01\"[PDAT] : \"2017/10/02\"[PDAT]))))",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "table under heading <# Suchfrage> (column 1)",
      "text": "Row 1: \nRow 2: #14\nRow 3: #15",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "table under heading <# Suchfrage> (column 1)",
      "text": "Row 1: #|Suchfrage\nRow 2: #1|\nRow 3: #2|\nRow 4: #3|\nRow 5: #4|\nRow 6: #5|\nRow 7: #6|\nRow 8: #7|\nRow 9: #8|\nRow 10: #9|",
      "start_page": 38,
      "end_page": 38
    }
  ]
}